EP0656889A1 - 9-chloroprostaglandin esters and amides and their use in the preparation of drugs - Google Patents
9-chloroprostaglandin esters and amides and their use in the preparation of drugsInfo
- Publication number
- EP0656889A1 EP0656889A1 EP93918946A EP93918946A EP0656889A1 EP 0656889 A1 EP0656889 A1 EP 0656889A1 EP 93918946 A EP93918946 A EP 93918946A EP 93918946 A EP93918946 A EP 93918946A EP 0656889 A1 EP0656889 A1 EP 0656889A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- chloro
- cyclohexyl
- pentanor
- dihydroxy
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002148 esters Chemical class 0.000 title claims abstract description 25
- 150000001408 amides Chemical class 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims description 10
- 229940079593 drug Drugs 0.000 title abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 239000000460 chlorine Substances 0.000 claims description 15
- 229910052801 chlorine Inorganic materials 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 230000004410 intraocular pressure Effects 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 239000002798 polar solvent Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 150000003254 radicals Chemical class 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical class [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 claims description 5
- 230000036772 blood pressure Effects 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 230000027119 gastric acid secretion Effects 0.000 claims description 5
- 230000035876 healing Effects 0.000 claims description 5
- 230000029860 luteolysis Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 4
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 150000001718 carbodiimides Chemical class 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- POCFBDFTJMJWLG-UHFFFAOYSA-N dihydrosinapic acid methyl ester Natural products COC(=O)CCC1=CC(OC)=C(O)C(OC)=C1 POCFBDFTJMJWLG-UHFFFAOYSA-N 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 26
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- -1 heterocyclic radical Chemical class 0.000 description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- VZAWCLCJGSBATP-UHFFFAOYSA-N 1-cycloundecyl-1,2-diazacycloundecane Chemical compound C1CCCCCCCCCC1N1NCCCCCCCCC1 VZAWCLCJGSBATP-UHFFFAOYSA-N 0.000 description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- 239000012230 colorless oil Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000003480 eluent Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 150000003180 prostaglandins Chemical class 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 4
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- PPNCOQHHSGMKGI-UHFFFAOYSA-N 1-cyclononyldiazonane Chemical compound C1CCCCCCCC1N1NCCCCCCC1 PPNCOQHHSGMKGI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000007171 acid catalysis Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000008327 renal blood flow Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- ZAUYNCUCMJDAHW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;hydrogen peroxide;molecular iodine Chemical compound OO.II.C=CN1CCCC1=O ZAUYNCUCMJDAHW-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010069102 Thromboxane-A synthase Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- ABLXLDHMDSSQAP-UHFFFAOYSA-N diethylamino-(dimethylamino-ethoxy-methoxymethyl)-(hydroxymethyl)-methylazanium Chemical compound OC[N+](C(N(C)C)(OCC)OC)(C)N(CC)CC ABLXLDHMDSSQAP-UHFFFAOYSA-N 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000021190 leftovers Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
Definitions
- the present invention relates to esters and amides of 9-chloro-prostaglandin analogues, processes for their preparation, their use as medicaments and pharmaceutical preparations containing these esters and amides.
- prostaglandins It is known from the extensive state of the art of prostaglandins and their analogues that this class of substances is suitable for the treatment of mammals, including humans, on account of their biological and pharmacological properties. "However, their use as medicinal products is difficult. Most natural prostaglandins have a duration of action that is too short for therapeutic purposes because they are broken down too quickly by various enzymatic processes. All structural changes therefore have the aim of both the duration of action and the selectivity to increase the effect.
- 9-chloro prostaglandin analogues are pharmacologically and medically valuable active substances, the production and use of e.g. for cytoprotection, ulcer healing, inhibition of gastric acid secretion, luteolysis, lowering blood pressure, or inhibiting platelet aggregation are described in EP 299 914 and WO 86/05488. These substances have a significantly improved specificity and activity compared to the corresponding natural prostaglandins with a similar spectrum of activity.
- Hydrogen atom an alkyl or cycloalkyl, aryl or heterocyclic radical or R ⁇ the radical CONHR3 with R3 in the meaning of an acid radical or the radical R2 and
- W is a free or functionally modified hydroxymethylene group or a free or functionally modified CH 3
- Alkylene group with 3-10 C atoms which may optionally be substituted by fluorine atoms and
- R4 is a free or functionally modified hydroxy group
- R5 is a hydrogen atom, an alkyl, a halogen substituted alkyl, a
- Cycloalkyl an optionally substituted aryl or a heterocyclic group, and if R2 has the meaning of a hydrogen atom, the salts thereof with physiologically compatible bases and the cyclodextrin clathrates thereof are known, but the esters of the present invention are neither mentioned in detail nor particularly emphasized.
- 9-chlorine atom can be ⁇ - or ß-permanent
- R1 represents the radical OR2 with R2 in the meaning of a hydrogen atom, alkyl,
- W is a free or functionally modified hydroxymethylene group or a free one
- OH group can be ⁇ or ⁇
- D is a straight-chain or branched-chain alkylene group with 1-10 C atoms, which is optionally substituted by fluorine atoms, and
- E is an oxygen or sulfur atom or a direct bond
- R4 is a free or functionally modified hydroxy group
- R5 is an alkyl, a halogen-substituted alkyl, cycloalkyl, an optionally substituted aryl or heterocyclic group and if R ⁇ has the meaning of a hydroxyl group, the salts of which mean physiologically compatible bases, but the esters of these are also known there Invention neither mentioned in detail nor particularly emphasized.
- 9-chloro-prostaglandin derivatives are pharmacologically and medically valuable active substances, their production and use, for example for cytoprotection, ulcer healing, inhibition of gastric acid secretion, luteolysis, lowering blood pressure, or inhibition of platelet aggregation, are described in EP 299 914, EP 30 377 and WO 86/05488 are. Compared to the corresponding natural prostaglandins, these substances have a significantly improved specificity and longer action with a similar spectrum of activity.
- esters or amides of 9-chloro- ⁇ ⁇ - or 9-chloro-3-oxa- ⁇ ⁇ -prostaglandins are particularly suitable for external use, in particular for the treatment of increased intraocular pressure (glaucoma). This application is not mentioned in the prior art mentioned above.
- the invention relates to pharmaceutical preparations containing esters and amides of 9-chloro-prostaglandins of the formula I.
- Rl COOR 2 wherein R 2 is an optionally substituted C3-C1 Q - CycloalkyhCg-Cio-Aryl- or C6-C ⁇ o-Ar (-CC-C4) alkyl radical, or CONHR ⁇ with R ⁇ in the meaning of an optionally substituted C ⁇ -C ⁇ o-alkyl radical, mean for the treatment of increased intraocular pressure and pharmaceutical preparations containing 9-chloro-prostaglandin esters and amides of the general formula (I)
- X is oxygen or CH 2 , R 1 COOR2, where R 2 is an optionally substituted phenacyl radical, or CONHR 3 with R 3 is an optionally substituted C j -Ci Q alkyl-
- the rest mean as medically valuable active ingredients for use for e.g. the treatment of increased intraocular pressure, cytoprotection, ulcer healing, inhibition of gastric acid secretion, luteolysis, lowering blood pressure or inhibition of platelet aggregation.
- the invention also relates to 9-chloro-prostaglandin esters and amides of the general formula I.
- X is oxygen or CH2, Rl COOR 2 , where R 2 is an optionally substituted phenacyl radical, or CONHR 3 with R 3 is an optionally substituted C j -Ci Q alkyl-
- the invention also relates to the use of the 9-chloroprostaglandin derivatives mentioned in these pharmaceutical preparations for the production of medicaments for the treatment of increased intraocular pressure.
- esters according to the invention which are not mentioned in EP 299 914 and EP 30 377 are surprisingly particularly suitable for local use, and also have a diuretic effect and promote renal blood flow.
- the invention thus also relates to esters of 9-chloro-prostaglandins of the general formula I.
- X is oxygen or CH2
- Rl COOR 2 where R 2 is an optionally substituted C2-C3 alkyl
- Suitable substituents for the phenacyl radical R 2 are straight-chain or branched ⁇ -04- alkyl radicals such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl and the halogen atoms chlorine, bromine and iodine.
- Alkyl groups R 2 are straight or branched alkyl groups with 1-10 C atoms, such as methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, decyl.
- the alkyl groups R 2 may optionally be substituted several times by halogen atoms, hydroxyl groups, alkoxy groups, dialkylamino and trialkylammonium groups, or optionally substituted aryl or aroyl groups.
- substituents are fluorine, chlorine or bromine, hydroxy, methoxy, ethoxy, dimethylamino, diethylamino, trimethylammonium, phenyl, benzoyl, bromobenzoyl, iodobenzoyl, methylbenzoyl.
- Preferred alkyl groups R 2 are those with 1-5 C atoms, such as, for example, methyl, ethyl, propyl, isobutyl, butyl, tert-butyl and fluorine, hydroxyl, methoxy and benzoyl as preferred substituents. Hydroxy and benzoyl are particularly preferred substituents.
- alkyl groups R 3 straight-chain or branched alkyl groups with 1-10 C atoms are to be considered, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl.
- the alkyl groups R 3 can optionally be mono- to polysubstituted by halogen atoms, hydroxyl groups, alkoxy groups, or optionally substituted aryl groups. Examples of substituents are fluorine, chlorine or bromine, hydroxy, methoxy, ethoxy and phenyl.
- Preferred alkyl groups R 3 are those with 1-5 C atoms, such as methyl, ethyl, propyl, isopropyl, isobutyl, butyl, and preferred substituents fluorine, hydroxy and methoxy.
- Suitable aryl groups R 2 are both substituted and unsubstituted aryl groups, such as, for example, phenyl, 1-naphthyl and 2-naphthyl, which can each be substituted by 1-3 halogen atoms, one phenyl group, 1-3 alkyl groups each with 1-4 C. -Atoms, a chloromethyl, fluoromethyl, trifluoromethyl, carboxyl, hydroxy or alkoxy group with 1-4 C atoms.
- the substituents in the 3- and 4-position on the phenyl ring are preferred, for example by fluorine, chlorine, alkoxy or trifluoromethyl or in the 4-position by hydroxy.
- the benzyl group is preferred as the aralkyl group R 2 .
- the cycloalkyl group R 2 can contain 3-10, preferably 5 and 6 carbon atoms in the ring.
- the rings can be substituted by alkyl groups with 1-4 carbon atoms his. Examples include cyclopentyl, cyclohexyl, methylcyclohexyl and adamantyl.
- Both substituted and unsubstituted aryl groups such as, for example, phenyl, 1-naphthyl and 2-naphthyl, which can each be substituted by 1-3 halogen atoms, a phenyl group, 1-3, are suitable for the aryl groups as substituents of the alkyl radicals R 3 Alkyl groups with 1-4 C atoms each, a chloromethyl, fluoromethyl, trifluoromethyl, carboxyl, hydroxy or alkoxy group with 1-4 C atoms.
- the substituents in the 3- and 4-position on the phenyl ring are preferred, for example by fluorine, chlorine, alkoxy or trifluoromethyl or in the 4-position by hydroxy.
- the invention further relates to a process for the preparation of the 9-chloro-prostaglandin esters and amides of the formula I, characterized in that a) a compound of the formula II
- Hai is chlorine or bromine, converted into compounds of the general formula (Ia) in a polar solvent
- bases for the reaction of compounds of general formula II with compounds of general formula III are the bases known to the person skilled in the art, e.g. Triethylamine, diisopropylethylamine, diazabicycloundecene, diazabicyclononane, N, N-dimethylaminopyridine, potassium carbonate or cesium carbonate are particularly suitable.
- the reaction can be carried out in all polar solvents, e.g. Acetone, acetonitrile, dimethylformamide or dimethyl sulfoxide.
- polar solvents e.g. Acetone, acetonitrile, dimethylformamide or dimethyl sulfoxide.
- the carboxy compounds are reacted, for example, with diazo hydrocarbons in a manner known per se.
- the esterifications with diazo hydrocarbons take place, for. Example, that a solution of the diazo hydrocarbon in an inert solvent, preferably in diethyl ether, with the carboxy compound in the same or in a different solvent, such as. B. methylene chloride mixed.
- Diazoalkanes are either known or can be prepared by known methods [Org. Reactions Vol. 8, pages 389-394 (1954)].
- ester group CO2R 2 for R 1 in which R 2 represents an alkyl group with 1-10 C atoms, which may also be substituted, is carried out according to methods known to the person skilled in the art.
- the carboxy compounds are, for example, with the corresponding alkyl halide, preferably alkyl bromide or alkyl iodide, in the presence of a base, such as, for example, triethylamine, diazabicylononane (DBN), diazabicycloundecane (DBU) in an inert solvent, for example Acetonitrile, tetrahydrofuran, methylene chloride or dimethylformamide at temperatures between -80 ° C and 100 ° C, preferably at 0 ° C to 30 ° C, esterified.
- a base such as, for example, triethylamine, diazabicylononane (DBN), diazabicycloundecane (DBU) in an inert solvent, for example Ace
- esters of tertiary alcohols are converted from the carboxy compound in an inert solvent, preferably methylene chloride with acid catalysis and boron trifluoride etherate with the corresponding alkene at temperatures between -100 ° C and + 50 ° C, preferably between -78 ° C and 0 ° C, manufactured.
- Orthophosphoric acid is preferably used for acid catalysis.
- ester group CO2R for. in which R 2 represents a substituted or unsubstituted aryl group takes place according to the methods known to the person skilled in the art.
- the carboxy compounds with the corresponding arylhydroxy compounds are reacted with dicyclohexylcarbodiimide in the presence of a suitable base, for example pyridine, DMAP, triethylamine, diazabicyclononane (DBN), diazabicycloundecane (DBU), in an inert solvent.
- Suitable solvents are methylene chloride, ethylene chloride, chloroform, ethyl acetate, tetrahydrofuran, preferably chloroform.
- the reaction is carried out at temperatures between -30 ° C and + 50 ° C, preferably at temperatures between 0 ° C and room temperature.
- the introduction of the amide group CONHR- * for Rl is preferably carried out from the ester group by aminolysis with the corresponding amine R ⁇ NH2, ie the corresponding ester is preferably without solvent or in an inert solvent, such as acetonitrile or dimethylformamide, with the corresponding amine for several Heated between 40 ° C and 140 ° C, preferably 60 ° C to 90 ° C.
- the starting materials required for the synthesis of the esters and amides can be obtained from EP 299 914 and WO 86/05488.
- Cyclodextrin clathrates can be obtained analogously to a regulation in WO 87/05294.
- the invention also relates to a process for the preparation of esters of 9-chloroprostaglandins of the formula I in which
- X is oxygen or CH2
- Rl COOR 2 wherein R 2 represents an optionally substituted C2-C3 alkyl, cyclopentyl, cyclohexyl, phenyl or benzyl radical, characterized in that a compound of the
- bases known to the person skilled in the art for example diazabicyclononane, diazabicycloundecene, diisopropylethylamine, N, N-dimethylammopyridine, pyridine, triethylamine, potassium carbonate or cesium carbonate, are particularly suitable as bases for the reaction of compounds of the general formula II with compounds of the general formula III 1 or with phenol .
- the reactions can be carried out in polar solvents, e.g. Acetone, acetonitrile, chloroform, diethyl ether, dimethylformamide, dimethyl sulfoxide, methylene chloride or tetrahydrofuran.
- polar solvents e.g. Acetone, acetonitrile, chloroform, diethyl ether, dimethylformamide, dimethyl sulfoxide, methylene chloride or tetrahydrofuran.
- esters and amides of 9-chloro-prostaglanin analogues prepared according to this invention are chemically stable PGD derivatives. They are valuable pharmaceuticals because they have a significantly improved (higher specificity) and, above all, much longer effects than the corresponding natural prostaglandins with a similar spectrum of activity.
- the compounds according to the invention can also be used in combination, for example with ⁇ -blockers, diuretics, phosphodiesterase inhibitors, calcium antagonists, thromboxane antagonists, thromboxane synthetase and cyclooxygenase inhibitors, anticoagulant substances, as well as fibrinolytics, leukotriene antagomes, leukemia antigens and antigen antigen.
- the compounds according to the invention are particularly suitable for local use, for example to promote blood circulation to the skin and to lower increased intraocular pressure (glaucoma), as well as to promote renal blood flow and for use as a diuretic.
- the single dose of the compounds for use in the treatment of increased intraocular pressure is 1 ng - 100 ⁇ g I eye, once or several times a day, if they are administered locally to human patients.
- the dose of the compounds when used topically to promote skin circulation is 5-500 ng / cm 2 when administered to human patients.
- Solutions, lotions, ointments, creams or plasters, for example, are suitable for local application for use to promote blood circulation in the skin.
- the invention also relates to medicaments based on the compounds of the formula I, and their cyclodextrin clathrates, with the customary auxiliaries and excipients.
- the active compounds according to the invention are intended to be used in conjunction with the auxiliaries known and customary in galenics, e.g. for the preparation of preparations for promoting skin circulation, for treating increased intraocular pressure (glaucoma), for promoting kidney circulation or for use as a diuretic.
- Example 1 r5Z.13EVr9R.llR.15SV9-chloro-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-penta- nor-5,13-prostadienoic acid phenacylester
- IR liquid cap.: 3310 (br.), 3100, 3008, 2927, 2853, 1643, 1630, 1553, 1448, 1348, 1260, 1080, 1072, 1003, 970 cm " 1 .
- 16,17,18,19,20-pentanor-5,13-prostadienoic acid methyl ester from Example 6 are mixed with 149.7 mg of 3-amino-l-propanol and stirred for 24 hours at 80 ° C under argon.
- the reaction mixture is purified by column chromatography on silica gel. With CH2CI2 / 0 - 50% methanol as the eluent, 49.6 mg of the title compound are obtained as a colorless oil.
- IR liquid cap.: 3362 (br.), 3023, 2928, 2854, 1657, 1543, 1450, 1335, 1304, 1273, 1102, 1006, 972 cm " 1 .
- Example 10 r5Z.13EVr9R.llR.15SV9-chloro-3-oxa-l5-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-pentanor-5.13-prostadienoic acid isopropyl ester
- To 190 mg (5Z, 13E) - (9R, IIR, 15S) -9-chloro-3-oxa-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor-5,13 -prostadienic acid is added 4.7 ml of a solution of acetonitrile, diazabicycloundecane (DBU) and 2-iodopropane (50 ml acetonitrile, 0.8 ml DBU, 0.8 ml 2-iodopropane) and stirred for 18 hours at 24 ° C under argon.
- DBU diazabic
- Hairiess rats (female) are weighed (200-250g), anesthetized with 0.5ml 25% urethane in 0.9% NaCl / 100g / kg (2/3 ip, 1/3 sc) and placed on a preheated hot plate from Fa. Jowitherm laid.
- a circular area of 34 mm in diameter is marked on the abdomen approximately 2 cm below the tip of the sternum.
- One test substance is applied per animal, which was assigned with the randomization program RDRK.
- 5% isopropyl myristate in ethanol is used as solvent.
- 20 ml of the respective test solution are applied evenly with an Eppendorf pipette.
- the treated skin is divided into three measuring areas, each with an 18mm diameter, and marked.
- the blood flow to the skin is measured 2 and 4 hours (and possibly 6 hours) after application with a laser double flow meter (company Perimed). Triple measurements are made on each animal at the marked points.
- the blood flow to the skin was determined using the non-invasive laser Doppler method. The measurements were carried out 4 hours after the local application of the substances on the abdominal skin of anesthetized (urethane) hairless rats *. Isopropyl myristate in ethanol was used as solvent (5/95; v v).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention concerns 9-chloroprostaglandin esters and amides of general formula (I), methods of preparing them and their use as drugs.
Description
9-Chlor-prostaglandin-ester und -amide und ihre Verwendung für die Herstellung von Arzneimitteln 9-chloro-prostaglandin esters and amides and their use in the manufacture of medicines
Gegenstand der vorliegenden Erfindung sind Ester und Amide von 9-Chlor-prostaglan- dinanaloga, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese Ester und Amide enthaltende pharmazeutische Präparate.The present invention relates to esters and amides of 9-chloro-prostaglandin analogues, processes for their preparation, their use as medicaments and pharmaceutical preparations containing these esters and amides.
Aus dem umfangreichen Stand der Technik der Prostaglandine und ihrer Analoga weiß man, daß diese Stoffklasse aufgrund ihrer biologischen und pharmakologischen Eigen¬ schaften zur Behandlung von Säugetieren, einschließlich des Menschen, geeignet ist. "Ihre Verwendung als Arzneimittel stößt jedoch auf Schwierigkeiten. Die meisten natürlichen Prostaglandine besitzen eine für therapeutische Zwecke zu kurze Wirkdauer, da sie zu rasch durch verschiedene enzymatische Prozesse abgebaut werden. Alle Strukturverände¬ rungen haben daher das Ziel, sowohl die Wirkdauer als auch die Selektivität der Wirkung zu steigern.It is known from the extensive state of the art of prostaglandins and their analogues that this class of substances is suitable for the treatment of mammals, including humans, on account of their biological and pharmacological properties. "However, their use as medicinal products is difficult. Most natural prostaglandins have a duration of action that is too short for therapeutic purposes because they are broken down too quickly by various enzymatic processes. All structural changes therefore have the aim of both the duration of action and the selectivity to increase the effect.
9-Chlor-prostaglandinanaloga sind pharmakologisch und medizinisch wertvolle Wirkstoffe, deren Herstellung und Anwendung z.B. zur Zytoprotektion, Ulkusheilung, Hemmung der Magensäuresekretion, Luteolyse, Blutdrucksenkung, oder Plättchen- aggregationshemmung in EP 299 914 und WO 86/05488 beschrieben sind. Diese Substanzen besitzen gegenüber den entsprechenden natürlichen Prostaglandinen bei ähnlichem Wirkungsspektrum eine wesentlich verbesserte Spezifität und Wirkung.9-chloro prostaglandin analogues are pharmacologically and medically valuable active substances, the production and use of e.g. for cytoprotection, ulcer healing, inhibition of gastric acid secretion, luteolysis, lowering blood pressure, or inhibiting platelet aggregation are described in EP 299 914 and WO 86/05488. These substances have a significantly improved specificity and activity compared to the corresponding natural prostaglandins with a similar spectrum of activity.
Aus EP 299 914 sind 9-Chlor-3-oxa-prostaglandin-Derivate der allgemeinen FormelFrom EP 299 914 9-chloro-3-oxa-prostaglandin derivatives of the general formula
worin wherein
Z die Reste
oder
Z the leftovers or
Hai ein α- oder ß-ständiges Chlor- oder Fluoratom, den Rest CH2OH oder COOR2 mit R2 in der Bedeutung einesShark an α- or ß-standing chlorine or fluorine atom, the rest CH2OH or COOR2 with R2 in the meaning of a
Wasserstoffatoms, eines Alkyl- oder Cycloalkyl-, Aryl- oder heterocyclischen Restes oder R^ den Rest CONHR3 mit R3 in der Bedeutung eines Säurerestes oder des Restes R2 undHydrogen atom, an alkyl or cycloalkyl, aryl or heterocyclic radical or R ^ the radical CONHR3 with R3 in the meaning of an acid radical or the radical R2 and
A eine -CH2-CH2-, eine trans -CH=CH- oder eine -C≡C-GruppeA is a -CH2-CH2-, a trans -CH = CH- or a -C≡C group
W eine freie oder funktioneil abgewandelte Hydroxymethylengruppe oder eine freie oder funktionell abgewandelte CH3 W is a free or functionally modified hydroxymethylene group or a free or functionally modified CH 3
OH Gruppe, wobei die jeweiligen OH-Gruppen α- oder ß-ständig sein können, D und E gemeinsam eine direkte Bindung oderOH group, where the respective OH groups can be α or β, D and E together a direct bond or
D eine geradkettige mit 1-10, eine verzweigtkettige mit 2-10 oder eine ringförmigeD a straight chain with 1-10, a branched chain with 2-10 or an annular one
Alkylengruppe mit 3-10 C- Atomen, die gegebenenfalls durch Fluoratome substituiert sein können undAlkylene group with 3-10 C atoms, which may optionally be substituted by fluorine atoms and
E ein Sauerstoff- oder Schwefelatom, eine direkte Bindung, eine -C≡C- Bindung oder eine -CRg=CR7-Gruppe darstellt, wobei Rg und R7 sich unterscheiden und ein Wasserstoffatom, ein Chloratom oder eine Cι-C4-Alkylgruppe bedeuten,E represents an oxygen or sulfur atom, a direct bond, a -C≡C bond or a -CRg = CR7 group, where Rg and R7 differ and denote a hydrogen atom, a chlorine atom or a C 1 -C 4 -alkyl group,
R4 eine freie oder funktionell abgewandelte Hydroxygruppe,R4 is a free or functionally modified hydroxy group,
R5 ein Wasserstoffatom, eine Alkyl-, eine Halogen-substituierte Alkyl-, eineR5 is a hydrogen atom, an alkyl, a halogen substituted alkyl, a
Cycloalkyl-, eine gegebenenfalls substituierte Aryl- oder eine heterocyclische Gruppe, und falls R2 die Bedeutung eines Wasserstoffatoms hat, deren Salze mit physiologisch verträglichen Basen bedeuten und deren Cyclodextrinclathrate bekannt, jedoch werden die Ester der vorliegenden Erfindung weder im einzelnen genannt noch besonders hervorgehoben.Cycloalkyl, an optionally substituted aryl or a heterocyclic group, and if R2 has the meaning of a hydrogen atom, the salts thereof with physiologically compatible bases and the cyclodextrin clathrates thereof are known, but the esters of the present invention are neither mentioned in detail nor particularly emphasized.
Aus EP 30 377 sind 9-Chlor-ρrostaglandin-Derivate
From EP 30 377 are 9-chloro-ρrostaglandin derivatives
woπn das 9-Chloratom α- oder ß-ständig sein kann,where the 9-chlorine atom can be α- or ß-permanent,
Rl den Rest OR2 mit R2 in der Bedeutung eines Wasserstoffatoms, Alkyl,R1 represents the radical OR2 with R2 in the meaning of a hydrogen atom, alkyl,
Cycloalkyl, Aryl oder eines heterocyclischen Restes oder den Rest NHR3 mit R3 in der Bedeutung eines Säurerestes oder Wasserstoffatoms undCycloalkyl, aryl or a heterocyclic radical or the radical NHR3 with R3 in the meaning of an acid radical or hydrogen atom and
A eine -CH2-CH2- oder eis -CH=CH- Gruppe,A is a -CH2-CH2 or eis -CH = CH- group,
B eine -CH2-CH2-, trans -CH=CH- oder eine -C≡C- Gruppe,B is a -CH2-CH2-, trans -CH = CH- or a -C≡C group,
W eine freie oder funktionell abgewandelte Hydroxymethylengruppe oder eine freieW is a free or functionally modified hydroxymethylene group or a free one
CH3 CH 3
oder funktionell abgewandelte OH Gruppe, wobei die OH-Gruppe α oder ß- ständig sein kann,or functionally modified OH group, where the OH group can be α or β,
D und E gemeinsam eine direkte Bindung oderD and E together have a direct bond or
D eine geradkettige oder verzweigtkettige Alkylengruppe mit 1-10 C-Atomen, die gegebenenfalls durch Fluoratome substituiert ist, undD is a straight-chain or branched-chain alkylene group with 1-10 C atoms, which is optionally substituted by fluorine atoms, and
E ein Sauerstoff- oder Schwefelatom oder eine direkte Bindung undE is an oxygen or sulfur atom or a direct bond and
R4 eine freie oder funktionell abgewandelte Hydroxygruppe,R4 is a free or functionally modified hydroxy group,
R5 eine Alkyl-, eine Halogen-substituierte Alkyl-, Cycloalkyl-, eine gegebenenfalls substituierte Aryl- oder heterocyclische Gruppe und falls R^ die Bedeutung einer Hydroxylgruppe hat, deren Salze mit physiologisch verträglichen Basen bedeuten, bekannt, jedoch werden auch dort die Ester dieser Erfindung weder im einzelnen genannt noch besonders hervorgehoben.
9-Chlor-Prostaglandin-Derivate sind pharmakologisch und medizinisch wertvolle Wirkstoffe, deren Herstellung und Anwendung z.B. zur Zytoprotektion, Ulkusheilung, Hemmung der Magensäuresekretion, Luteolyse, Blutdrucksenkung, oder Plättchenaggre- gationshemmung in EP 299 914, EP 30 377 und WO 86/05488 beschrieben sind. Diese Substanzen besitzen gegenüber den entsprechenden natürlichen Prostaglandinen bei ähnlichem Wirkungsspektrum eine wesentlich verbesserte Spezifltät und längere Wirkung.R5 is an alkyl, a halogen-substituted alkyl, cycloalkyl, an optionally substituted aryl or heterocyclic group and if R ^ has the meaning of a hydroxyl group, the salts of which mean physiologically compatible bases, but the esters of these are also known there Invention neither mentioned in detail nor particularly emphasized. 9-chloro-prostaglandin derivatives are pharmacologically and medically valuable active substances, their production and use, for example for cytoprotection, ulcer healing, inhibition of gastric acid secretion, luteolysis, lowering blood pressure, or inhibition of platelet aggregation, are described in EP 299 914, EP 30 377 and WO 86/05488 are. Compared to the corresponding natural prostaglandins, these substances have a significantly improved specificity and longer action with a similar spectrum of activity.
Es wurde nun gefunden, daß die neuen 9-Chlor-prostaglandinester und -amide eine hohe Wirkspezifität, bessere Wirksamkeit, längere Wirkdauer und vor allen Dingen höhere Stabilität als die natürlichen Prostaglandine besitzen.It has now been found that the new 9-chloro-prostaglandin esters and amides have a high specificity of action, better effectiveness, longer duration of action and, above all, higher stability than the natural prostaglandins.
Es wurde ebenfalls gefunden, daß Ester bzw. Amide von 9-Chlor-Δ^- bzw. 9-Chlor-3-oxa- Δ^-prostaglandinen für die äußeren Anwendungen, insbesondere zur Behandlung erhöhten Augeninnendruckes (Glaukom) besonders geeignet sind. Diese Anwendung wird in dem oben angeführten Stand der Technik nicht erwähnt.It has also been found that esters or amides of 9-chloro-Δ ^ - or 9-chloro-3-oxa- Δ ^ -prostaglandins are particularly suitable for external use, in particular for the treatment of increased intraocular pressure (glaucoma). This application is not mentioned in the prior art mentioned above.
Die Erfindung betrifft pharmazeutische Präparate enthaltend Ester und Amide von 9- Chlor-prostaglandinen der Formel IThe invention relates to pharmaceutical preparations containing esters and amides of 9-chloro-prostaglandins of the formula I.
worinwherein
X Sauerstoff oder CH2,X oxygen or CH2,
Rl COOR2, wobei R2 einen gegebenenfalls substituierten
C3-C1Q- CycloalkyhCg-Cio-Aryl- oder C6-Cιo-Ar(Cι-C4)-alkyl-Rest darstellt, oder CONHR^ mit R^ in der Bedeutung eines gegebenenfalls substituierten
Cι-Cιo-Alkyl-Restes, bedeuten, zur Behandlung erhöhten Augeninnendruckes sowie pharmazeutische Präparate enthaltend 9-Chlor-prostaglandinester und -amide der allgemeinen Formel (I)Rl COOR 2 , wherein R 2 is an optionally substituted C3-C1 Q - CycloalkyhCg-Cio-Aryl- or C6-Cιo-Ar (-CC-C4) alkyl radical, or CONHR ^ with R ^ in the meaning of an optionally substituted Cι-Cιo-alkyl radical, mean for the treatment of increased intraocular pressure and pharmaceutical preparations containing 9-chloro-prostaglandin esters and amides of the general formula (I)
woπn woπn
X Sauerstoff oder CH2, R1 COOR2, wobei R2 einen gegebenenfalls substituierten Phenacyl-Rest darstellt, oder CONHR3 mit R3 in der Bedeutung eines gegebenenfalls substituierten Cj-CiQ-Alkyl-X is oxygen or CH 2 , R 1 COOR2, where R 2 is an optionally substituted phenacyl radical, or CONHR 3 with R 3 is an optionally substituted C j -Ci Q alkyl-
Restes, bedeuten, als medizinisch wertvolle Wirkstoffe zur Anwendung für z.B. die Behandlung erhöhten Augeninnendruckes, Zytoprotektion, Ulkusheilung, Hemmung der Magensäuresekretion, Luteolyse, Blutdrucksenkung oder Plättchenaggregationshemmung.The rest, mean as medically valuable active ingredients for use for e.g. the treatment of increased intraocular pressure, cytoprotection, ulcer healing, inhibition of gastric acid secretion, luteolysis, lowering blood pressure or inhibition of platelet aggregation.
Die Erfindung betrifft außerdem 9-Chlor-prostaglandinester und -amide der allgemeinen Formel IThe invention also relates to 9-chloro-prostaglandin esters and amides of the general formula I.
(I),
woπn ι (I), woπn ι
X Sauerstoff oder CH2, Rl COOR2, wobei R2 einen gegebenenfalls substituierten Phenacyl-Rest darstellt, oder CONHR3 mit R3 in der Bedeutung eines gegebenenfalls substituierten Cj-CiQ-Alkyl-X is oxygen or CH2, Rl COOR 2 , where R 2 is an optionally substituted phenacyl radical, or CONHR 3 with R 3 is an optionally substituted C j -Ci Q alkyl-
Restes, bedeuten.Rest, mean.
Die Erfindung betrifft auch die Verwendung der in diesen pharmazeutischen Präparaten genannten 9-Chlorprostaglandinderivaten zur Herstellung von Arzneimitteln zur Behand¬ lung des erhöhten Augeninnendrucks.The invention also relates to the use of the 9-chloroprostaglandin derivatives mentioned in these pharmaceutical preparations for the production of medicaments for the treatment of increased intraocular pressure.
Es wurde weiterhin gefunden, daß die nicht in EP 299 914 und EP 30 377 genannten, erfindungsgemäßen Ester überraschenderweise besonders für die lokale Anwendung geeignet sind, sowie diuretische Wirkung zeigen und die Nierendurchblutung fördern.It has also been found that the esters according to the invention which are not mentioned in EP 299 914 and EP 30 377 are surprisingly particularly suitable for local use, and also have a diuretic effect and promote renal blood flow.
Die Erfindung betrifft somit auch Ester von 9-Chlor-prostaglandinen der allgemeinen Formel IThe invention thus also relates to esters of 9-chloro-prostaglandins of the general formula I.
ClCl
worin wherein
X Sauerstoff oder CH2, undX is oxygen or CH2, and
Rl COOR2, wobei R2 einen gegebenenfalls substituierten C2-C3-Alkyl-,Rl COOR 2 , where R 2 is an optionally substituted C2-C3 alkyl,
Cyclopentyl-, Cyclohexyl-, Phenyl- oder Benzyl-Rest darstellt, bedeuten und deren Cyclodextrinclathrate.Cyclopentyl, cyclohexyl, phenyl or benzyl radical, mean and their cyclodextrin clathrates.
Als Substituenten für den Phenacylrest R2 kommen geradkettige oder verzweigte ^-04- Alkyl-Reste wie Methyl, Ethyl, Propyl, Isopropyl, Butyl, Isobutyl und tert.-Butyl sowie die Halogenatome Chlor, Brom und Iod in Betracht.
Als Alkylgruppen R2 sind gerade oder verzweigte Alkylgruppen mit 1-10 C-Atomen zu betrachten, wie beispielsweise Methyl, Ethyl, Propyl, Butyl, Isobutyl, tert.-Butyl, Pentyl, Isopentyl, Neopentyl, Hexyl, Heptyl, Decyl. Die Alkylgruppen R2 können gegebenenfalls mehrfach substituiert sein durch Halogenatome, Hydroxygruppen, Alkoxygruppen, Dial- kylamino- und Trialkylammoniumgruppen, oder gegebenenfalls substituierte Aryl- bzw. Aroylgruppen. Als Substituenten seien beispielsweise genannt Fluor, Chlor oder Brom, Hydroxy, Methoxy, Ethoxy, Dimethylamino, Diethylamino, Trimethylammonium, Phenyl, Benzoyl, Brombenzoyl, Iodbenzoyl, Methylbenzoyl. Als bevorzugte Alkylgruppen R2 sind solche mit 1-5 C-Atomen, wie z.B. Methyl, Ethyl, Propyl, Isobutyl, Butyl , tert.-Butyl und als bevorzugte Substituenten Fluor, Hydroxy, Methoxy und Benzoyl zu nennen. Besonders bevorzugte Substituenten sind Hydroxy und Benzoyl.Suitable substituents for the phenacyl radical R 2 are straight-chain or branched ^ -04- alkyl radicals such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl and the halogen atoms chlorine, bromine and iodine. Alkyl groups R 2 are straight or branched alkyl groups with 1-10 C atoms, such as methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, decyl. The alkyl groups R 2 may optionally be substituted several times by halogen atoms, hydroxyl groups, alkoxy groups, dialkylamino and trialkylammonium groups, or optionally substituted aryl or aroyl groups. Examples of substituents are fluorine, chlorine or bromine, hydroxy, methoxy, ethoxy, dimethylamino, diethylamino, trimethylammonium, phenyl, benzoyl, bromobenzoyl, iodobenzoyl, methylbenzoyl. Preferred alkyl groups R 2 are those with 1-5 C atoms, such as, for example, methyl, ethyl, propyl, isobutyl, butyl, tert-butyl and fluorine, hydroxyl, methoxy and benzoyl as preferred substituents. Hydroxy and benzoyl are particularly preferred substituents.
Als Alkylgruppen R3 sind geradkettige oder verzweigte Alkylgruppen mit 1-10 C-Atomen zu betrachten, wie beispielsweise Methyl, Ethyl, Propyl, Isopropyl, Butyl, Isobutyl, tert.- Butyl, Pentyl, Isopentyl, Neopentyl, Hexyl, Heptyl. Die Alkylgruppen R3 können gegebe¬ nenfalls ein- bis mehrfach substituiert sein durch Halogenatome, Hydroxygruppen, Alk¬ oxygruppen, oder gegebenenfalls substituierte Arylgruppen. Als Substituenten seien bei¬ spielsweise genannt Fluor, Chlor oder Brom, Hydroxy, Methoxy, Ethoxy, Phenyl. Als be¬ vorzugte Alkylgruppen R3 sind solche mit 1-5 C-Atomen, wie z.B. Methyl, Ethyl, Propyl, Isopropyl, Isobutyl, Butyl, und als bevorzugte Substituenten Fluor, Hydroxy und Methoxy zu nennen.As alkyl groups R 3 , straight-chain or branched alkyl groups with 1-10 C atoms are to be considered, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl. The alkyl groups R 3 can optionally be mono- to polysubstituted by halogen atoms, hydroxyl groups, alkoxy groups, or optionally substituted aryl groups. Examples of substituents are fluorine, chlorine or bromine, hydroxy, methoxy, ethoxy and phenyl. Preferred alkyl groups R 3 are those with 1-5 C atoms, such as methyl, ethyl, propyl, isopropyl, isobutyl, butyl, and preferred substituents fluorine, hydroxy and methoxy.
Als Arylgruppen R2 kommen sowohl substituierte wie auch unsubstituierte Arylgruppen in Betracht, wie beispielsweise Phenyl, 1-Naphtyl und 2-Naphthyl, die jeweils substituiert sein können durch 1-3 Halogenatome, eine Phenylgruppe, 1-3 Alkylgruppen mit jeweils 1- 4 C-Atomen, eine Chlormethyl, Fluormethyl-, Trifluormethyl-, Carboxyl-, Hydroxy- oder Alkoxygruppe mit 1-4 C-Atomen. Bevorzugt sind die Substituenten in 3- und 4-Stellung am Phenylring, zum Beispiel durch Fluor, Chlor, Alkoxy oder Trifluormethyl oder in 4- Stellung durch Hydroxy.Suitable aryl groups R 2 are both substituted and unsubstituted aryl groups, such as, for example, phenyl, 1-naphthyl and 2-naphthyl, which can each be substituted by 1-3 halogen atoms, one phenyl group, 1-3 alkyl groups each with 1-4 C. -Atoms, a chloromethyl, fluoromethyl, trifluoromethyl, carboxyl, hydroxy or alkoxy group with 1-4 C atoms. The substituents in the 3- and 4-position on the phenyl ring are preferred, for example by fluorine, chlorine, alkoxy or trifluoromethyl or in the 4-position by hydroxy.
Als Aralkylgruppe R2 wird die Benzylgruppe bevorzugt.The benzyl group is preferred as the aralkyl group R 2 .
Die Cycloalkylgruppe R2 kann im Ring 3-10, vorzugsweise 5 und 6 Kohlenstoffatome enthalten. Die Ringe können durch Alkylgruppen mit 1-4 Kohlenstoffatomen substituiert
sein. Beispielsweise seien genannt Cyclopentyl, Cyclohexyl, Methylcyclohexyl und Adamantyl.The cycloalkyl group R 2 can contain 3-10, preferably 5 and 6 carbon atoms in the ring. The rings can be substituted by alkyl groups with 1-4 carbon atoms his. Examples include cyclopentyl, cyclohexyl, methylcyclohexyl and adamantyl.
Für die Arylgruppen als Substituenten der Alkylreste R3 kommen sowohl substituierte wie auch unsubstituierte Arylgruppen in Betracht, wie beispielsweise Phenyl, 1-Naphtyl und 2- Naphthyl, die jeweils substituiert sein können durch 1-3 Halogenatome, eine Phenylgrup- pe, 1-3 Alkylgruppen mit jeweils 1-4 C-Atomen, eine Chlormethyl, Fluormethyl-, Trifluormethyl-, Carboxyl-, Hydroxy- oder Alkoxygruppe mit 1-4 C-Atomen. Bevorzugt sind die Substituenten in 3- und 4-Stellung am Phenylring, zum Beispiel durch Fluor, Chlor, Alkoxy oder Trifluormethyl oder in 4-Stellung durch Hydroxy.Both substituted and unsubstituted aryl groups, such as, for example, phenyl, 1-naphthyl and 2-naphthyl, which can each be substituted by 1-3 halogen atoms, a phenyl group, 1-3, are suitable for the aryl groups as substituents of the alkyl radicals R 3 Alkyl groups with 1-4 C atoms each, a chloromethyl, fluoromethyl, trifluoromethyl, carboxyl, hydroxy or alkoxy group with 1-4 C atoms. The substituents in the 3- and 4-position on the phenyl ring are preferred, for example by fluorine, chlorine, alkoxy or trifluoromethyl or in the 4-position by hydroxy.
Die Erfindung betrifft ferner ein Verfahren zur Herstellung der 9-Chlor-prostaglandinester und -amide der Formel I, dadurch gekennzeichnet, daß man a) eine Verbindung der Formel IIThe invention further relates to a process for the preparation of the 9-chloro-prostaglandin esters and amides of the formula I, characterized in that a) a compound of the formula II
woπnwoπn
X die oben angegebene Bedeutung aufweist, unter Zusatz einer geeigneten Base mit einem gegebenenfalls substituierten Halogenaceto- phenonderivat der allgemeinen Formel IIIX has the meaning given above, with the addition of a suitable base with an optionally substituted haloacetophenone derivative of the general formula III
(HI)
woπn (HI) woπn
R4 CrC -Alkyl-, Chlor, Brom oder Iod undR 4 C r C alkyl, chlorine, bromine or iodine and
Hai Chlor oder Brom bedeuten, in einem polaren Lösungsmittel zu Verbindungen der allgemeinen Formel (la) umsetzt,Hai is chlorine or bromine, converted into compounds of the general formula (Ia) in a polar solvent,
oder b) einen Alkylester der allgemeinen Formel Ib or b) an alkyl ester of the general formula Ib
woπnwoπn
X die oben angegebene Bedeutung aufweist, ohne Lösungsmittel mit einem Amin der allgemeinen Formel IVX has the meaning given above, without solvent with an amine of the general formula IV
H2N-H 2 N-
(IV)(IV)
zu Verbindungen der allgemeinen Formel Ic
umsetzt.to compounds of the general formula Ic implements.
Als Base für die Umsetzung von Verbindungen der allgemeinen Formel II mit Verbindun¬ gen der allgemeinen Formel III sind die dem Fachmann bekannten Basen, z.B. Triethyl- amin, Diisopropylethylamin, Diazabicycloundecen, Diazabicyclononan, N,N-Dimethyl- aminopyridin, Kaliumcarbonat oder Cäsiumcarbonat besonders geeignet.As bases for the reaction of compounds of general formula II with compounds of general formula III are the bases known to the person skilled in the art, e.g. Triethylamine, diisopropylethylamine, diazabicycloundecene, diazabicyclononane, N, N-dimethylaminopyridine, potassium carbonate or cesium carbonate are particularly suitable.
Die Umsetzung kann in allen polaren Lösungsmitteln, z.B. Aceton, Acetonitril, Dimethyl- formamid oder Dimethylsulfoxid erfolgen.The reaction can be carried out in all polar solvents, e.g. Acetone, acetonitrile, dimethylformamide or dimethyl sulfoxide.
Die Einführung der Estergruppe CO2R2 für R1, bei welcher R2 eine Alkylgruppe mit 1-10 C-Atomen darstellt, erfolgt nach den dem Fachmann bekannten Methoden. Die Carboxy- verbindungen werden beispielsweise mit Diazokohlenwasserstoffen in an sich bekannter Weise umgesetzt. Die Veresterungen mit Diazokohlenwasserstoffen erfolgt z. B. dadurch, daß man eine Lösung des Diazokohlenwasserstoffes in einem inerten Lösungsmittel, vorzugsweise in Diethylether, mit der Carboxyverbindung in dem gleichen oder in einem anderen Lösungsmittel, wie z. B. Methylenchlorid, vermischt. Nach beendeter Umsetzung in 1 bis 30 Minuten wird das Lösungsmittel entfernt und der Ester in üblicher Weise gereinigt. Diazoalkane sind entweder bekannt oder können nach bekannten Methoden hergestellt werden [Org. Reactions Bd. 8, Seite 389 - 394 (1954)].The introduction of the ester group CO2R 2 for R 1 , in which R 2 represents an alkyl group with 1-10 C atoms, takes place according to the methods known to the person skilled in the art. The carboxy compounds are reacted, for example, with diazo hydrocarbons in a manner known per se. The esterifications with diazo hydrocarbons take place, for. Example, that a solution of the diazo hydrocarbon in an inert solvent, preferably in diethyl ether, with the carboxy compound in the same or in a different solvent, such as. B. methylene chloride mixed. When the reaction has ended in 1 to 30 minutes, the solvent is removed and the ester is purified in the customary manner. Diazoalkanes are either known or can be prepared by known methods [Org. Reactions Vol. 8, pages 389-394 (1954)].
Die Einführung der Estergruppe CO2R2 für R1, bei welcher R2 eine Alkylgruppe mit 1-10 C-Atomen darstellt, die gegebenenfalls auch substituiert sein kann, erfolgt nach den dem Fachmann bekannten Methoden. Die Carboxyverbindungen werden beispielsweise mit dem entsprechenden Alkylhalogenid, bevorzugt Alkylbromid oder Alkyliodid, in Gegenwart einer Base, wie beispielsweise Triethylamin, Diazabicylononan (DBN), Diazabicycloundecan (DBU) in einem inerten Lösungsmittel, wie beispielsweise
Acetonitril, Tetrahydrofuran, Methylenchlorid oder Dimethylformamid bei Temperaturen zwischen -80°C und 100°C, vorzugsweise bei 0°C bis 30°C, verestert.The introduction of the ester group CO2R 2 for R 1 , in which R 2 represents an alkyl group with 1-10 C atoms, which may also be substituted, is carried out according to methods known to the person skilled in the art. The carboxy compounds are, for example, with the corresponding alkyl halide, preferably alkyl bromide or alkyl iodide, in the presence of a base, such as, for example, triethylamine, diazabicylononane (DBN), diazabicycloundecane (DBU) in an inert solvent, for example Acetonitrile, tetrahydrofuran, methylene chloride or dimethylformamide at temperatures between -80 ° C and 100 ° C, preferably at 0 ° C to 30 ° C, esterified.
Die Synthese der Phenacylester (5Z,13E)-(9R,llR,15S)-9-Chlor-15-cyclohexyl-ll,15-di- hydroxy-16,17,18,19,20-pentanor-5,13-prostadiensäurεphenacylester und (5Z,13E)- (9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl-ll,15-dihydroxy-16,17,18,19,20-pentanor- 5,13-prostadiensäurephenacylester in den Beispielen 1 und 3 ist allgemein anwendbar als Verfahren zur Herstellung von Phenacylestern von 9-Chlor-Prostaglandinderivaten.The synthesis of the phenacyl esters (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-di-hydroxy-16,17,18,19,20-pentanor-5,13- prostadienoic acid phenacyl ester and (5Z, 13E) - (9R, IIR, 15S) -9-chloro-3-oxa-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor- 5,13- Phenadyl ester of prostadienate in Examples 1 and 3 is generally applicable as a process for the preparation of phenacyl esters of 9-chloro-prostaglandin derivatives.
Speziell Ester tertiärer Alkohole werden aus der Carboxyverbindung in einem inerten Lö¬ sungsmittel vorzugsweise Methylenchlorid unter Säurekatalyse und Bortrifluorid-Etherat mit dem entsprechenden Alken bei Temperaturen zwischen -100°C und +50°C, vorzugsweise zwischen -78°C und 0°C, hergestellt. Für die Säurekatalyse wird vorzugsweise Orthophosphorsäure verwendet.Especially esters of tertiary alcohols are converted from the carboxy compound in an inert solvent, preferably methylene chloride with acid catalysis and boron trifluoride etherate with the corresponding alkene at temperatures between -100 ° C and + 50 ° C, preferably between -78 ° C and 0 ° C, manufactured. Orthophosphoric acid is preferably used for acid catalysis.
Die Einführung der Estergruppe CO2R für . bei welcher R2 eine substituierte oder un- substituierte Arylgruppe darstellt, erfolgt nach den dem Fachmann bekannten Methoden. Beispielsweise werden die Carboxyverbindungen mit den entsprechenden Arylhydroxyverbindungen mit Dicyclohexylcarbodiimid in Gegenwart einer geeigneten Base, beispielsweise Pyridin, DMAP, Triethylamin, Diazabicyclononan (DBN), Diazabicycloundecan (DBU), in einem inerten Lösungsmittel umgesetzt. Als Lösungsmittel kommen Methylenchlorid, Ethylenchlorid, Chloroform, Essigester, Tetrahydrofuran, vorzugsweise Chloroform in Frage. Die Reaktion wird bei Temperaturen zwischen -30°C und +50°C, vorzugsweise bei Temperaturen zwischen 0°C und Raumtemperatur, durchgeführt.The introduction of the ester group CO2R for. in which R 2 represents a substituted or unsubstituted aryl group takes place according to the methods known to the person skilled in the art. For example, the carboxy compounds with the corresponding arylhydroxy compounds are reacted with dicyclohexylcarbodiimide in the presence of a suitable base, for example pyridine, DMAP, triethylamine, diazabicyclononane (DBN), diazabicycloundecane (DBU), in an inert solvent. Suitable solvents are methylene chloride, ethylene chloride, chloroform, ethyl acetate, tetrahydrofuran, preferably chloroform. The reaction is carried out at temperatures between -30 ° C and + 50 ° C, preferably at temperatures between 0 ° C and room temperature.
Die Einführung der Amidgruppe CONHR-* für Rl erfolgt vorzugsweise aus der Estergruppe durch Aminolyse mit dem entsprechenden Amin R^NH2, d.h. der entsprechende Ester wird vorzugsweise ohne Lösungsmittel oder in einem inerten Lösungsmittel, wie beispielsweise Acetonitril oder Dimethylformamid, mit dem entsprechenden Amin für mehrere Stunden zwischen 40°C und 140°C, vorzugsweise 60°C bis 90°C erhitzt. ~"
Die Synthese der Amide (5Z,13E)-(9R,llR,15S)-9-Chlor-15-cyclohexyl-ll,15-dihydroxy- 16,17,18,19,20-pentanor-5,13-prostadiensäure-(3-hydroxypropyl)-amid und (5Z,13E)- (9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl-ll,15-dihydroxy-16,17,18,19,20-pentanor- 5,13-prostadiensäure-(3-hydroxypropyl)-amid in den Beispielen 2 und 4 ist allgemein anwendbar als Verfahren zur Herstellung der Amide von 9-Chlor-Prostaglandinderivaten.The introduction of the amide group CONHR- * for Rl is preferably carried out from the ester group by aminolysis with the corresponding amine R ^ NH2, ie the corresponding ester is preferably without solvent or in an inert solvent, such as acetonitrile or dimethylformamide, with the corresponding amine for several Heated between 40 ° C and 140 ° C, preferably 60 ° C to 90 ° C. ~ " The synthesis of the amides (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic acid- (3-hydroxypropyl) amide and (5Z, 13E) - (9R, IIR, 15S) -9-chloro-3-oxa-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20- Pentanor-5,13-prostadienoic acid (3-hydroxypropyl) amide in Examples 2 and 4 is generally applicable as a process for the preparation of the amides of 9-chloro-prostaglandin derivatives.
Die für die Synthese der Ester und Amide benötigten Ausgangsmaterialien sind nach Vor¬ schriften aus EP 299 914 und WO 86/05488 zu erhalten.The starting materials required for the synthesis of the esters and amides can be obtained from EP 299 914 and WO 86/05488.
Cyclodextrinclathrate können analog einer Vorschrift in WO 87/05294 erhalten werden.Cyclodextrin clathrates can be obtained analogously to a regulation in WO 87/05294.
Die Erfindung betrifft außerdem ein Verfahren zur Herstellung von Estern der 9-Chlor- prostaglandine der Formel I worinThe invention also relates to a process for the preparation of esters of 9-chloroprostaglandins of the formula I in which
X Sauerstoff oder CH2, undX is oxygen or CH2, and
Rl COOR2, wobei R2 einen gegebenenfalls substituierten C2-C3-Alkyl-, Cyclopentyl, Cyclohexyl-, Phenyl- oder Benzyl-Rest darstellt, bedeuten, dadurch gekennzeichnet, daß man in an sich bekannter Weise eine Verbindung derRl COOR 2 , wherein R 2 represents an optionally substituted C2-C3 alkyl, cyclopentyl, cyclohexyl, phenyl or benzyl radical, characterized in that a compound of the
Formel IIFormula II
ClCl
worin X die oben angegebene Bedeutung hat,where X has the meaning given above,
A. entweder in Gegenwart einer geeigneten Base in einem polaren Lösungsmittel mit einer Verbindung der allgemeinen Formel III*A. either in the presence of a suitable base in a polar solvent with a compound of the general formula III *
Hal-R2 (HI' )
worin R2 die oben angegebenen Bedeutung hat, jedoch nicht Phenyl bedeutet, und Hai für Chlor, Brom oder Iod steht,bei Temperaturen zwischen -80°C und 100°C umsetzt, und den entstandenen Ester isoliert o.'erHal-R 2 (HI ') wherein R 2 has the meaning given above, but does not mean phenyl, and shark represents chlorine, bromine or iodine, is reacted at temperatures between -80 ° C and 100 ° C, and the resulting ester is isolated or otherwise
B.in Gegenwart einer geeigneten Base in einem polaren Lösungsmittel nach Aktivierung mit einem Carbodiimid wie z. B. Dicycloliexylcarbodiimid mit Phenol bei Temperaturen zwischen -30°C und 50°C umsetzt und den entstandenen Ester isoliert.B. in the presence of a suitable base in a polar solvent after activation with a carbodiimide such. B. dicycloliexylcarbodiimide with phenol at temperatures between -30 ° C and 50 ° C and the resulting ester isolated.
Als Base für die Umsetzung von Verbindungen der allgemeinen Formel II mit Verbindungen der allgemeinen Formel III1 oder mit Phenol sind die dem Fachmann bekannten Basen, z.B. Diazabicyclononan, Diazabicycloundecen, Diisopropylethylamin, N,N-Dimethylammopyridin, Pyridin, Triethylamin, Kaliumcarbonat oder Cäsiumcarbonat besonders geeignet.The bases known to the person skilled in the art, for example diazabicyclononane, diazabicycloundecene, diisopropylethylamine, N, N-dimethylammopyridine, pyridine, triethylamine, potassium carbonate or cesium carbonate, are particularly suitable as bases for the reaction of compounds of the general formula II with compounds of the general formula III 1 or with phenol .
Die Umsetzungen können in polaren Lösungsmitteln, z.B. Aceton, Acetonitril, Chloroform, Diethylether, Dimethylformamid, Dimethylsulfoxid, Methylenchlorid oder Tetrahydrofuran erfolgen.The reactions can be carried out in polar solvents, e.g. Acetone, acetonitrile, chloroform, diethyl ether, dimethylformamide, dimethyl sulfoxide, methylene chloride or tetrahydrofuran.
Die entsprechend dieser Erfindung hergestellten Ester und Amide von 9-Chlor-Prostaglan- dinanaloga sind chemisch stabile PGD-Derivate. Sie stellen wertvolle Pharmaka dar, da sie bei ähnlichem Wirkungsspektram eine wesentlich verbesserte (höhere Spezifität) und vor allem wesentlich längere Wirkung aufweisen als die entsprechenden natürlichen Prostaglandine.The esters and amides of 9-chloro-prostaglanin analogues prepared according to this invention are chemically stable PGD derivatives. They are valuable pharmaceuticals because they have a significantly improved (higher specificity) and, above all, much longer effects than the corresponding natural prostaglandins with a similar spectrum of activity.
Sie sind als medizinisch wertvolle Wirkstoffe zur Anwendung für z.B. Blutdrucksenkung, die Förderung der Hautdurchblutung, Luteolyse, Hemmung der Magensäuresekretion, Plättchenaggregationshemmung, Ulkusheilung oder Zytoprotektion geeignet.They are used as medically valuable active ingredients for e.g. Lowering blood pressure, promoting skin circulation, luteolysis, inhibiting gastric acid secretion, inhibiting platelet aggregation, ulcer healing or cytoprotection.
Die erfindungsgemäßen Verbindungen können auch in Kombination, z.B. mit ß-Blockern, Diuretika, Phosphodiesterasehemmern, Calciumantagonisten, Thromboxanantagonisten, Thromboxansynthetase- und Cyclooxygenasehemmern, gerinnungshemmenden Substan¬ zen, wie auch Fibrinolytika, Leukotrienantagomsten, Leukotriensynthetasehemmern und Antigestagenen, verwendet werden.
Besonders geeignet sind die erfindungsgemäßen Verbindungen zur lokalen Anwendung wie z.B. zur Förderung der Hautdurchblutung und zur Senkung erhöhten Augeninnendruckes (Glaukom), sowie zur Förderung der Nierendurchblutung und zur Verwendung als Diuretikum.The compounds according to the invention can also be used in combination, for example with β-blockers, diuretics, phosphodiesterase inhibitors, calcium antagonists, thromboxane antagonists, thromboxane synthetase and cyclooxygenase inhibitors, anticoagulant substances, as well as fibrinolytics, leukotriene antagomes, leukemia antigens and antigen antigen. The compounds according to the invention are particularly suitable for local use, for example to promote blood circulation to the skin and to lower increased intraocular pressure (glaucoma), as well as to promote renal blood flow and for use as a diuretic.
Bei Kaninchen bewirkt die lokale Applikation der Verbindungen eine Senkung des Au¬ geninnendruckes.In rabbits, the local application of the compounds causes a reduction in the intraocular pressure.
Bei Affen mit experimentellem Glaukom bewirkt die lokale Applikation der Verbindungen eine Normalisierung des pathologisch erhöhten Augeninnendruckes.In monkeys with experimental glaucoma, the local application of the compounds normalizes the pathologically increased intraocular pressure.
Die Einzeldosis der Verbindungen für die Anwendung zur Behandlung erhöhten Augenin¬ nendruckes ist 1 ng - 100 μg I Auge, einmal oder mehrmals täglich, wenn sie am mensch¬ lichen Patienten lokal verabreicht werden.The single dose of the compounds for use in the treatment of increased intraocular pressure is 1 ng - 100 μg I eye, once or several times a day, if they are administered locally to human patients.
Für die lokale Applikation , wie z. B. für die Anwendung zur Behandlung erhöhten Augeninnendruckes sind beispielsweise Lösungen, Lotionen oder Salben geeignet.For local application, such as B. for use in the treatment of increased intraocular pressure, for example solutions, lotions or ointments are suitable.
Die Dosis der Verbindungen bei lokaler Anwendung zur Förderung der Hautdurchblutung ist 5-500 ng/cm2, wenn sie am menschlichen Patienten verabreicht werden.The dose of the compounds when used topically to promote skin circulation is 5-500 ng / cm 2 when administered to human patients.
Für die lokale Applikation für die Anwendung zur Förderung der Hautdurchblutung sind beispielsweise Lösungen, Lotionen, Salben, Cremes oder Pflaster geeignet.Solutions, lotions, ointments, creams or plasters, for example, are suitable for local application for use to promote blood circulation in the skin.
Die Erfindung betrifft auch Arzneimittel auf Basis der Verbindungen der Formel I, sowie deren Cyclodextrinclathrate, mit den üblichen Hilfs- und Trägerstoffen.The invention also relates to medicaments based on the compounds of the formula I, and their cyclodextrin clathrates, with the customary auxiliaries and excipients.
Die erfindungsgemäßen Wirkstoffe sollen in Verbindung mit den in der Galenik bekannten und üblichen Hilfsstoffen, z.B. zur Herstellung von Präparaten zur Förderung der Haut¬ durchblutung, zur Behandlung des erhöhten Augeninnendruckes (Glaukom), zur Förde¬ rung der Nierendurchblutung oder zur Verwendung als Diuretikum dienen.The active compounds according to the invention are intended to be used in conjunction with the auxiliaries known and customary in galenics, e.g. for the preparation of preparations for promoting skin circulation, for treating increased intraocular pressure (glaucoma), for promoting kidney circulation or for use as a diuretic.
Die folgenden Beispiele sollen die Erfindung näher erläutern, ohne daß damit eine Begren¬ zung vorgenommen werden soll.
Beispiel 1 r5Z.13EVr9R.llR.15SV9-Chlor-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-penta- nor-5,13-prostadiensäurephenacylesterThe following examples are intended to explain the invention in more detail, without any intention that it should be limited. Example 1 r5Z.13EVr9R.llR.15SV9-chloro-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-penta- nor-5,13-prostadienoic acid phenacylester
Zu einer Lösung aus 100 mg (5Z,13E)-(9R,llR,15S)-9-Chlor-15-cyclohexyl-ll,15-dihy- droxy-16,17,18,19,20-pentanor-5,13-prostadiensäure und 75 mg w-Bromacetophenon in 2.6 ml Acetonitril gibt man 0.057 ml Triethylamin in 1.25 ml Aceton und rührt anschlie¬ ßend 18 Stunden bei 24°C unter Argon. Man gibt dann nochmal 40 mg w-Bromacetophe¬ non zu und rührt nochmals 16 Stunden bei 24°C unter Argon. Dann verdünnt man mit 80 ml Essigester, wäscht einmal mit 10 ml einer Mischung aus gesättigter Natriumchlorid-Lδ- sung und Wasser (1:1), trocknet über Natriumsulfat und engt im Vakuum ein. Das Roh¬ produkt reinigt man durch Säulenchromatographie an Kieselgel. Mit Hexan / 0 - 80% Es¬ sigester als Elutionsmittel erhält man 114 mg der Titelverbindung als farbloses Öl.To a solution of 100 mg (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor-5, 13-prostadienoic acid and 75 mg of w-bromoacetophenone in 2.6 ml of acetonitrile are added 0.057 ml of triethylamine in 1.25 ml of acetone and then stirred for 18 hours at 24 ° C. under argon. Then another 40 mg of w-bromoacetophe¬ non are added and the mixture is stirred for a further 16 hours at 24 ° C. under argon. Then diluted with 80 ml of ethyl acetate, washed once with 10 ml of a mixture of saturated sodium chloride solution and water (1: 1), dried over sodium sulfate and concentrated in vacuo. The crude product is purified by column chromatography on silica gel. With hexane / 0-80% ethyl acetate as the eluent, 114 mg of the title compound are obtained as a colorless oil.
IR (CHC13): 3607, 3400 (br.), 3065, 3030, 3003, 2928, 2857, 1742, 1705, 1600, 1450, 1376, 1155, 1084, 1002, 972 cm'1.IR (CHC1 3 ): 3607, 3400 (br.), 3065, 3030, 3003, 2928, 2857, 1742, 1705, 1600, 1450, 1376, 1155, 1084, 1002, 972 cm ' 1 .
Beispiel 2 r5Z.13EVr9R.llR.15SV9-Chlor-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-Denta- nor-5,13-prostadiensäure-f3-hvdroxypropylVamidExample 2 r5Z.13EVr9R.llR.15SV9-chloro-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-dentano-nor-5,13-prostadienoic acid-f3-hvdroxypropylVamid
86.4 mg (5Z,13E)-(9R,llR,15S)-9-Chlor-15-cyclohexyl-ll,15-dihydroxy-16,17,18,19,20- pentanor-5,13-prostadiensäuremethylester aus Beispiel 1 werden mit 157.3 mg 3-Amino- 1-propanol versetzt und 24 Stunden bei 80°C unter Argon gerührt. Das Reaktionsgemisch reinigt man durch Säulenchromatographie an Kieselgel. Mit CH2CI2 / 0 - 50% Methanol als Elutionsmittel erhält man 30.5 mg der Titelverbindung als farbloses Öl.86.4 mg (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic acid methyl ester from example 1 are mixed with 157.3 mg of 3-amino-1-propanol and stirred for 24 hours at 80 ° C. under argon. The reaction mixture is purified by column chromatography on silica gel. With CH2CI2 / 0 - 50% methanol as eluent, 30.5 mg of the title compound is obtained as a colorless oil.
IR (Flüssig-Kap.): 3310 (br.), 3100, 3008, 2927, 2853, 1643, 1630, 1553, 1448, 1348, 1260, 1080, 1072, 1003, 970 cm"1.IR (liquid cap.): 3310 (br.), 3100, 3008, 2927, 2853, 1643, 1630, 1553, 1448, 1348, 1260, 1080, 1072, 1003, 970 cm " 1 .
Beispiel 3 r5Z.13EVf9R.llR.15SV9-Chlor-3-oxa-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20- pentanor-5,13-prostadiensäurephenacylesterExample 3 r5Z.13EVf9R.llR.15SV9-chloro-3-oxa-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-pentanor-5,13-prostadienoic acid phenacylester
Zu einer Lösung aus 92 mg (5Z,13E)-(9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl-ll,15- dihydroxy-16,17,18,19,20-pentanor-5,13-prostadiensäure und 105 mg w-Bromacetophe¬ non in 2.5 ml Acetonitril gibt man 0.052 ml Triethylamin in 1.0 ml Aceton und rührt an-
schließend 18 Stunden bei 24°C unter Argon. Dann verdünnt man mit 60 ml Essigester, wäscht zweimal mit je 10 ml einer Mischung aus gesättigter Natriumchlorid-Lösung und Wasser (1:1), trocknet über Natriumsulfat und engt im Vakuum ein. Das Rohprodukt rei¬ nigt man durch Säulenchromatographie an Kieselgel. Mit Hexan / 0 - 80% Essigester als Elutionsmittel erhält man 82.6 mg der Titelverbindung als farbloses Öl.To a solution of 92 mg (5Z, 13E) - (9R, llR, 15S) -9-chloro-3-oxa-15-cyclohexyl-ll, 15-dihydroxy-16,17,18,19,20-pentanor- 5,13-prostadienoic acid and 105 mg w-bromoacetophe non in 2.5 ml acetonitrile are added 0.052 ml triethylamine in 1.0 ml acetone and stirred finally 18 hours at 24 ° C under argon. Then diluted with 60 ml of ethyl acetate, washed twice with 10 ml of a mixture of saturated sodium chloride solution and water (1: 1), dried over sodium sulfate and concentrated in vacuo. The crude product is purified by column chromatography on silica gel. With hexane / 0 - 80% ethyl acetate as the eluent, 82.6 mg of the title compound are obtained as a colorless oil.
IR (CHC13): 3605, 3410 (br.), 3030, 2998, 2927, 2853, 1763, 1730, 1704, 1600, 1450, 1375, 1245, 1190, 1180, 1127, 1000, 972 cm"1.IR (CHC1 3 ): 3605, 3410 (br.), 3030, 2998, 2927, 2853, 1763, 1730, 1704, 1600, 1450, 1375, 1245, 1190, 1180, 1127, 1000, 972 cm "1 .
Beispiel 4 r5Z.13EVr9R.llR.15SV9-Chlor-3-oxa-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20- pentanor-5.13-prostadiensäure-f3-hvdroxypropylVamidExample 4 r5Z.13EVr9R.llR.15SV9-chloro-3-oxa-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-pentanor-5.13-prostadienoic acid-f3-hvdroxypropylVamid
80 mg (5Z,13E)-(9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl-ll,15-dihydroxy-80 mg (5Z, 13E) - (9R, llR, 15S) -9-chloro-3-oxa-15-cyclohexyl-ll, 15-dihydroxy-
16,17,18,19,20-pentanor-5,13-prostadiensäuremethylester aus Beispiel 6 werden mit 149.7 mg 3-Amino-l-propanol versetzt und 24 Stunden bei 80°C unter Argon gerührt. Das Re¬ aktionsgemisch reinigt man durch Säulenchromatographie an Kieselgel. Mit CH2CI2 / 0 - 50% Methanol als Elutionsmittel erhält man 49.6 mg der Titelverbindung als farbloses Öl.16,17,18,19,20-pentanor-5,13-prostadienoic acid methyl ester from Example 6 are mixed with 149.7 mg of 3-amino-l-propanol and stirred for 24 hours at 80 ° C under argon. The reaction mixture is purified by column chromatography on silica gel. With CH2CI2 / 0 - 50% methanol as the eluent, 49.6 mg of the title compound are obtained as a colorless oil.
IR (Flüssig-Kap.): 3362 (br.), 3023, 2928, 2854, 1657, 1543, 1450, 1335, 1304, 1273, 1102, 1006, 972 cm"1.IR (liquid cap.): 3362 (br.), 3023, 2928, 2854, 1657, 1543, 1450, 1335, 1304, 1273, 1102, 1006, 972 cm " 1 .
Beispiel 5 f5Z.13EVr9R.llR.15SV9-Chlor-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20- pentanor-5.13-prostadiensäuremethylesterExample 5 f5Z.13EVr9R.llR.15SV9-chloro-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-pentanor-5.13-prostadienoic acid methyl ester
Zu einer Lösung von 27 mg (5Z,13E)-(9R,llR,15S)-9-Chlor-15-cyclohexyl-ll,15-di- hydroxy-16,17,18,19,20-pentanor-5,13-prostadiensäure in 10 ml Methylenchlorid tropft man bei 0°C unter Argon eine etherische Diazomethan-Lösung bis zur bleibenden Gelbfärbung, rührt 5 Minuten bei 0°C und engt anschließend im Vakuum ein. Den so erhaltenen Rückstand reinigt man durch Chromatographie an Kieselgel. Mit Hexan / 0- 80% Essigester erhält man 24 mg der Titelverbindung als farbloses Öl.To a solution of 27 mg (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-di-hydroxy-16,17,18,19,20-pentanor-5, 13-prostadienoic acid in 10 ml of methylene chloride is added dropwise at 0 ° C. under argon to an ethereal diazomethane solution until the color changes to yellow, the mixture is stirred at 0 ° C. for 5 minutes and then concentrated in vacuo. The residue thus obtained is purified by chromatography on silica gel. With hexane / 0-80% ethyl acetate, 24 mg of the title compound is obtained as a colorless oil.
IR (CHCI3): 3610, 3420 (br.), 3030, 3002, 2931, 2857, 1732, 1447, 1435, 1365, 1314, 1230 (br.), 1083, 995, 970 cm"1.
Beispiel 6 r5Z.13EVr9R.llR.15SV9-Chlor-15-cvclohexyl-ll.l5-dihvdroxy-16.17.18.19.20- pentanor-5,13-prostadiensäureethylesterIR (CHCI3): 3610, 3420 (br.), 3030, 3002, 2931, 2857, 1732, 1447, 1435, 1365, 1314, 1230 (br.), 1083, 995, 970 cm " 1 . Example 6 r5Z.13EVr9R.llR.15SV9-chloro-15-cvclohexyl-ll.l5-dihvdroxy-16.17.18.19.20-pentanor-5,13-prostadienoic acid ethyl ester
Zu 250 mg (5Z,13E)-(9R,llR,15S)-9-Chlor-15-cyclohexyl-ll,15-dihydroxy- 16,17,18,19,20-pentanor-5,13-prostadiensäure gibt man 6.25 ml einer Lösung aus Acetonitril, Diazabicycloundecan (DBU) und Iodethan (50 ml Acetonitril, 0.8 ml DBU, 0.8 ml Iodethan) und rührt 22 Stunden bei 24°C unter Argon. Anschließend verdünnt man mit 150 ml Essigester, wäscht einmal mit 5%iger Natriumhydrogencarbonat-Lösung, dreimal mit je 10 ml einer Mischung aus gesättigter Natriumchlorid-Lösung und Wasser (1:1), trocknet über Natriumsulfat und engt im Vakuum ein. Das Rohprodukt reinigt man durch Säulenchromatographie an Kieselgel. Mit Hexan / 0 - 80% Essigester als Elutionsmittel erhält man 129 mg der Titelverbindung als farbloses Öl.250 mg of (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic acid are added 6.25 ml of a solution of acetonitrile, diazabicycloundecane (DBU) and iodoethane (50 ml acetonitrile, 0.8 ml DBU, 0.8 ml iodoethane) and stir for 22 hours at 24 ° C under argon. Then diluted with 150 ml of ethyl acetate, washed once with 5% sodium hydrogen carbonate solution, three times with 10 ml of a mixture of saturated sodium chloride solution and water (1: 1), dried over sodium sulfate and concentrated in vacuo. The crude product is purified by column chromatography on silica gel. With hexane / 0 - 80% ethyl acetate as the eluent, 129 mg of the title compound are obtained as a colorless oil.
IR (CHC13): 3608, 3410 (br.), 3020, 3000, 2980, 2928, 2857, 1726, 1450, 1376, 1245, 1095, 1085, 973 cm"1.IR (CHC1 3 ): 3608, 3410 (br.), 3020, 3000, 2980, 2928, 2857, 1726, 1450, 1376, 1245, 1095, 1085, 973 cm " 1 .
Beispiel 7 r5Z.13EVr9R.llR.15SV9-Chlor-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20- pentanor-5.13-prostadiensäureisopropylesterExample 7 r5Z.13EVr9R.llR.15SV9-chloro-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-pentanor-5.13-prostadienoic acid isopropyl ester
Zu 100 mg (5Z,13E)-(9R,llR,15S)-9-Chlor-15-cyclohexyl-ll,15-dihydroxy- 16,17,18, 19,20-pentanor-5,13-prostadiensäure gibt man 2.5 ml einer Lösung aus Acetonitril, Diazabicycloundecan (DBU) und 2-Iodpropan (50 ml Acetonitril, 0.8 ml DBU, 0.8 ml 2-Iodpropan) und rührt 22 Stunden bei 24°C unter Argon. Anschließend verdünnt man mit 70 ml Essigester, wäscht zweimal mit je 10 ml einer Mischung aus gesättigter Natriumchlorid-Lösung und Wasser (1:1), trocknet über Natriumsulfat und engt im Vakuum ein. Das Rohprodukt reinigt man durch Säulenchromatographie an Kieselgel. Mit Hexan / 0 - 80% Essigester als Elutionsmittel erhält man 50.1 mg der Titelverbindung als farbloses Öl.100 mg of (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-dihydroxy-16,17,18, 19,20-pentanor-5,13-prostadienoic acid are added 2.5 ml of a solution of acetonitrile, diazabicycloundecane (DBU) and 2-iodopropane (50 ml acetonitrile, 0.8 ml DBU, 0.8 ml 2-iodopropane) and stirred for 22 hours at 24 ° C under argon. Then it is diluted with 70 ml of ethyl acetate, washed twice with 10 ml of a mixture of saturated sodium chloride solution and water (1: 1), dried over sodium sulfate and concentrated in vacuo. The crude product is purified by column chromatography on silica gel. With hexane / 0 - 80% ethyl acetate as the eluent, 50.1 mg of the title compound are obtained as a colorless oil.
IR (CHCI3): 3609, 3415 (br.), 3030, 3000, 2983, 2928, 2857, 1723, 1453, 1377, 1247, 1207, 1085, 973 cm"1.
Beispiel 8 r5Z.13EVf9R.llR.15SV9-Chlor-3-oxa-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20- pentanor-5.13-prostadiensäuremethvIesterIR (CHCI3): 3609, 3415 (br.), 3030, 3000, 2983, 2928, 2857, 1723, 1453, 1377, 1247, 1207, 1085, 973 cm " 1 . Example 8 r5Z.13EVf9R.llR.15SV9-chloro-3-oxa-15-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-pentanor-5.13-prostadienoic acid methyl ester
Zu einer Lösung von 300 mg (5Z,13E)-(9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl- ll,l5-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadiensäure in 30 ml Methylenchlorid tropft man bei 0°C unter Argon eine etherische Diazomethan-Lösung bis zur bleibenden Gelbfärbung, rührt 10 Minuten bei 0°C und engt anschließend im Vakuum ein. Den so erhaltenen Rückstand reinigt man durch Chromatographie an Kieselgel. Mit Hexan / 0- 80% Essigester erhält man 235 mg der Titelverbindung als farbloses Öl.To a solution of 300 mg (5Z, 13E) - (9R, llR, 15S) -9-chloro-3-oxa-15-cyclohexyl-ll, l5-dihydroxy-16,17,18,19,20-pentanor- 5,13-prostadienoic acid in 30 ml of methylene chloride is added dropwise at 0 ° C under argon, an ethereal diazomethane solution until the color changes to yellow, the mixture is stirred for 10 minutes at 0 ° C and then concentrated in vacuo. The residue thus obtained is purified by chromatography on silica gel. With hexane / 0-80% ethyl acetate, 235 mg of the title compound is obtained as a colorless oil.
IR (CHC13): 3607, 3408 (br.), 3033, 3000, 2927, 2854, 1752, 1450, 1442, 1377, 1347, 1280, 1123, 997, 973 cm"1.IR (CHC1 3 ): 3607, 3408 (br.), 3033, 3000, 2927, 2854, 1752, 1450, 1442, 1377, 1347, 1280, 1123, 997, 973 cm " 1 .
Beispiel 9 r5Z.13EVf9R.llR.15SV9-Chlor-3-oxa-15-cvclohexyl-ll.15-dihvdroxy-16.17.18.19.20- pentanor-5.13-prostadiensäureethylesterExample 9 r5Z.13EVf9R.llR.15SV9-chloro-3-oxa-15-cvclohexyl-ll.15-dihvdroxy-16.17.18.19.20-pentanor-5.13-prostadienoic acid ethyl ester
Zu 92 mg (5Z,13E)-(9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl-ll,15-dihydroxy- 16,17,18,19,20-pentanor-5,13-prostadiensäure gibt man 2.3 ml einer Lösung aus Acetonitril, Diazabicycloundecan (DBU) und Iodethan (50 ml Acetonitril, 0.8 ml DBU, 0.8 ml Iodethan) und rührt 18 Stunden bei 24°C unter Argon. Dann nochmals mit 0.73 ml einer Lösung aus 100 mg DBU in 10 ml Acetonitril versetzt und weitere 20 Stunden bei 24°C unter Argon gerührt. Anschließend verdünnt man mit 70 ml Essigester, wäscht einmal mit 10 ml einer 5%iger Natriumhydrogencarbonat-Lösung, dreimal mit je 10 ml einer Mischung aus gesättigter Natriumchlorid-Lösung und Wasser (1:1), trocknet über Natriumsulfat und engt im Vakuum ein. Das Rohprodukt reinigt man durch Säulenchromatographie an Kieselgel. Mit Hexan / 0 - 80% Essigester als Elutionsmittel erhält man 75.5 mg der Titelverbindung als farbloses Öl.To 92 mg (5Z, 13E) - (9R, IIR, 15S) -9-chloro-3-oxa-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor-5,13 -prostadienic acid is added 2.3 ml of a solution of acetonitrile, diazabicycloundecane (DBU) and iodoethane (50 ml acetonitrile, 0.8 ml DBU, 0.8 ml iodoethane) and stirred for 18 hours at 24 ° C under argon. Then again 0.73 ml of a solution of 100 mg DBU in 10 ml acetonitrile was added and the mixture was stirred for a further 20 hours at 24 ° C. under argon. Then diluted with 70 ml of ethyl acetate, washed once with 10 ml of a 5% sodium hydrogen carbonate solution, three times with 10 ml of a mixture of saturated sodium chloride solution and water (1: 1), dried over sodium sulfate and concentrated in vacuo. The crude product is purified by column chromatography on silica gel. With hexane / 0 - 80% ethyl acetate as the eluent, 75.5 mg of the title compound are obtained as a colorless oil.
IR (CHCI3): 3605, 3415 (br.), 3030, 2997, 2985, 2926, 2853, 1745, 1447, 1380, 1300, 1273, 1125, 1020, 997, 972 cm"1.IR (CHCI3): 3605, 3415 (br.), 3030, 2997, 2985, 2926, 2853, 1745, 1447, 1380, 1300, 1273, 1125, 1020, 997, 972 cm " 1 .
Beispiel 10 r5Z.13EVr9R.llR.15SV9-Chlor-3-oxa-l5-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20- pentanor-5.13-prostadiensäureisopropylester
Zu 190 mg (5Z,13E)-(9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl-ll,15-dihydroxy- 16,17,18,19,20-pentanor-5,13-prostadiensäure gibt man 4.7 ml einer Lösung aus Acetonitril, Diazabicycloundecan (DBU) und 2-Iodpropan (50 ml Acetonitril, 0.8 ml DBU, 0.8 ml 2-Iodpropan) und rührt 18 Stunden bei 24°C unter Argon. Anschließend verdünnt man mit 70 ml Essigester, wäscht zweimal mit je 20 ml einer Mischung aus gesättigter Natriumchlorid-Lösung und Wasser (1:1), trocknet über Natriumsulfat und engt im Vakuum ein. Das Rohprodukt reinigt man durch Säulenchromatographie an Kieselgel. Mit Hexan / 0 - 80% Essigester als Elutionsmittel erhält man 83.1 mg der Titelverbindung als farbloses Öl.Example 10 r5Z.13EVr9R.llR.15SV9-chloro-3-oxa-l5-cvclohexyl-11.15-dihvdroxy-16.17.18.19.20-pentanor-5.13-prostadienoic acid isopropyl ester To 190 mg (5Z, 13E) - (9R, IIR, 15S) -9-chloro-3-oxa-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor-5,13 -prostadienic acid is added 4.7 ml of a solution of acetonitrile, diazabicycloundecane (DBU) and 2-iodopropane (50 ml acetonitrile, 0.8 ml DBU, 0.8 ml 2-iodopropane) and stirred for 18 hours at 24 ° C under argon. Then it is diluted with 70 ml of ethyl acetate, washed twice with 20 ml of a mixture of saturated sodium chloride solution and water (1: 1), dried over sodium sulfate and concentrated in vacuo. The crude product is purified by column chromatography on silica gel. With hexane / 0 - 80% ethyl acetate as the eluent, 83.1 mg of the title compound are obtained as a colorless oil.
IR (CHC13): 3605, 3410 (br.), 3030, 3000, 2983, 2925, 2853, 1738, 1448, 1376, 1125, 1102, 997, 973 cm"1.IR (CHC1 3 ): 3605, 3410 (br.), 3030, 3000, 2983, 2925, 2853, 1738, 1448, 1376, 1125, 1102, 997, 973 cm " 1 .
Beispiel 11 r5Z.13EVr9R.llR.15SV9-Chlor-15 cvclohexyl-ll.15-dihvdroxy-3-oxa-16.17.18.19.20- pentanor-5.13-prostadiensäure-tert.-butylesterExample 11 r5Z.13EVr9R.llR.15SV9-chloro-15 cvclohexyl-ll.15-dihvdroxy-3-oxa-16.17.18.19.20-pentanor-5.13-prostadienoic acid tert-butyl ester
Zu einer Lösung von 2,54g (5Z,13E)-(9S,llR,l5S)-15-Cyclohexyl-9-hydroxy-3-oxa- ll,15-bis-(tetrahydropyran-2-yloxy)-16,17,18,19,20-pentanor-5,13-prostadiensäure-tert.- butylester in 25ml Pyridin gibt man bei 0°C 773mg Methansulfonsäurechlorid. Man rührt 4 Stunden bei 20°C und gibt dann die Lösung zu einer Suspension von 25,37g Tetrabutylammoniumchlorid in 20ml Toluol. Nach 15 stündigem Rühren bei 0°C wird noch 7 Stunden bei 40°C gerührt. Anschließend gibt man auf 250ml Eiswasser und extrahiert dreimal mit je 100ml Ether. Nachdem die organische Phase je zweimal mit 40ml gesättigter Natriumchloridlδsung gewaschen, über Magnesiumsulfat getrocknet und im Vakuum eingedampft wird, erhält man einen Rückstand, den man an Kieselgel mit Hexan/0-40% Ether chromatographiert. Man erhält 2,32g öligen (5Z, 13E)-(9R, 11R, 15S)-9-Chlor-15cyclohexyl-3-oxa-ll,15-bis-(tetrahydropyran-2-yloxy)-16,17,18,19,20- pentanor-5,13-prostadiensäure-tert.-butylester. Zur Abspaltung der Schutzgruppen rührt man den erhaltenen Ester mit 85ml einer Mischung aus Essigsäure/ Wasser/Tetrahydroruran (65/35/10) 24 Stunden bei 20°C. Nach Zugabe von Toluol und Eindampfen der Lösung im Vakuum chromatographiert man den Rückstand an Kieselgel. Mit Methylenchlorid/0,5% Aceton als Elutionsmittel erhält man 915mg der Titelverbindung als farbloses Öl JR (CHCI3): 3605, 3410, 2928, 1742, 1020, 974 cm"1
Beispiel 12To a solution of 2.54 g (5Z, 13E) - (9S, IIR, 15S) -15-cyclohexyl-9-hydroxy-3-oxal, 15-bis- (tetrahydropyran-2-yloxy) -16.17 , 18,19,20-pentanor-5,13-prostadienoic acid tert-butyl ester in 25 ml of pyridine are 773 mg of methanesulfonyl chloride at 0 ° C. The mixture is stirred for 4 hours at 20 ° C. and the solution is then added to a suspension of 25.37 g of tetrabutylammonium chloride in 20 ml of toluene. After stirring for 15 hours at 0 ° C., stirring is continued at 40 ° C. for 7 hours. Then add to 250 ml of ice water and extract three times with 100 ml of ether. After the organic phase has been washed twice with 40 ml of saturated sodium chloride solution, dried over magnesium sulfate and evaporated in vacuo, a residue is obtained which is chromatographed on silica gel with hexane / 0-40% ether. 2.32 g of oily (5Z, 13E) - (9R, 11R, 15S) -9-chloro-15cyclohexyl-3-oxa-II, 15-bis- (tetrahydropyran-2-yloxy) -16,17,18 are obtained. 19,20-pentanor-5,13-prostadienoic acid tert-butyl ester. To remove the protective groups, the ester obtained is stirred with 85 ml of a mixture of acetic acid / water / tetrahydroruran (65/35/10) at 20 ° C. for 24 hours. After adding toluene and evaporating the solution in vacuo, the residue is chromatographed on silica gel. With methylene chloride / 0.5% acetone as the eluent, 915 mg of the title compound are obtained as a colorless oil JR (CHCI3): 3605, 3410, 2928, 1742, 1020, 974 cm " 1 Example 12
Messung der HautdurchblutungMeasurement of skin circulation
Hairiess Ratten (weiblich) werden gewogen (200-250g), mit 0,5ml 25% Urethan in 0,9% NaCl /100g/kg (2/3 i.p., 1/3 s.c.) narkotisiert und auf eine vorgeheizte Wärmeplatte der Fa. Jowitherm gelegt.Hairiess rats (female) are weighed (200-250g), anesthetized with 0.5ml 25% urethane in 0.9% NaCl / 100g / kg (2/3 ip, 1/3 sc) and placed on a preheated hot plate from Fa. Jowitherm laid.
Auf dem Abdomen wird eine kreisförmige Fläche von 34mm Durchmesser ca. 2cm unter¬ halb der Sternumspitze markiert. Pro Tier wird eine Testsubstanz appliziert, die mit dem Randomisierungsprogramm RDRK zugeordnet wurde. Als Lösungsmittel wird 5% Isopro- pylmyristat in Ethanol verwendet. 20 ml der jeweiligen Testlösung werden mit einer Ep- pendorf-Pipette gleichmäßig aufgetragen. Danach wird die behandelte Haut nochmals in drei Meßflächen von jeweils 18mm Druchmesser unterteilt und markiert. Die Hautdurch¬ blutung wird 2 und 4 Stunden ( und gegebenenfalls 6 Stunden) nach der Applikation mit einem Laser Doppier Flowmeter (Firma Perimed) gemessen. Es werden an jedem Tier Dreifachmessungen an den markierten Stellen durchgeführt.A circular area of 34 mm in diameter is marked on the abdomen approximately 2 cm below the tip of the sternum. One test substance is applied per animal, which was assigned with the randomization program RDRK. 5% isopropyl myristate in ethanol is used as solvent. 20 ml of the respective test solution are applied evenly with an Eppendorf pipette. Then the treated skin is divided into three measuring areas, each with an 18mm diameter, and marked. The blood flow to the skin is measured 2 and 4 hours (and possibly 6 hours) after application with a laser double flow meter (company Perimed). Triple measurements are made on each animal at the marked points.
Beispiel 13Example 13
Messung der HautdurchblutungMeasurement of skin circulation
Die Hautdurchblutung wurde mit der nichtinvasiven Laser-Doppler Methode bestimmt. Die Messsungen wurden 4 Stunden nach der lokalen Applikation der Substanzen auf der Bauchhaut von narkotisierten ( Urethan ) haarlosen Ratten* durchgeführt. Als Lösungsmittel wurde Isopropylmyristat in Ethanol verwendet ( 5/95; v v ).The blood flow to the skin was determined using the non-invasive laser Doppler method. The measurements were carried out 4 hours after the local application of the substances on the abdominal skin of anesthetized (urethane) hairless rats *. Isopropyl myristate in ethanol was used as solvent (5/95; v v).
* Für diese Untersuchungen wurden weibliche Ratten ( Wister; hairiess ) mit einem Körpergewicht von 200-250g verwendet.
* Female rats (Wister; hairiess) with a body weight of 200-250g were used for these studies.
Claims
1) Pharmazeutische Präparate enthaltend Ester und Amide von 9-Chlor-prostaglandinen der Formel (I)1) Pharmaceutical preparations containing esters and amides of 9-chloro-prostaglandins of the formula (I)
worinwherein
X Sauerstoff oder CH2,X oxygen or CH2,
R1 COOR2, wobei R2 einen gegebenenfalls substituierten Ci-CiQ-Alkyl-, C3-C10- Cycloalkyl-jCg-Cio-Aryl- oder C6-Cιo-Ar(Cι-C4)-al yl-Rest darstellt, oder CONHR^ mit R^ in der Bedeutung eines gegebenenfalls substituiertenR 1 COOR 2 , wherein R 2 represents an optionally substituted Ci-CiQ-alkyl, C3-C10-cycloalkyl-jCg-Cio-aryl or C6-Cιo-Ar (Cι-C4) -al yl radical, or CONHR ^ with R ^ in the meaning of an optionally substituted
Ci-CiQ-Alkyl-Restes, bedeuten, zur Behandlung erhöhten Augeninnendruckes.Ci-Ci Q- alkyl residue, mean for the treatment of increased intraocular pressure.
2. Pharmazeutische Präparate enthaltend 9-Chlor-prostaglandinester und -amide der allgemeinen Formel I2. Pharmaceutical preparations containing 9-chloro-prostaglandin esters and amides of the general formula I
(I). woπn (I). woπn
X Sauerstoff oder CH2, R1 COOR2, wobei R2 einen gegebenenfalls substituierten Phenacyl-Rest darstellt, oder CONHR3 mit R3 in der Bedeutung eines gegebenenfalls substituierten Cj-CiQ-Alkyl-X is oxygen or CH 2 , R 1 COOR 2 , where R 2 is an optionally substituted phenacyl radical, or CONHR 3 with R 3 is an optionally substituted C j -Ci Q alkyl-
Restes, bedeuten, zur Behandlung erhöhten Augeninnendrackes und zur Zytoprotektion, Ulkusheilung, Hemmung der Magensäuresekretion, Luteolyse, Blutdracksenkung oder Plättchen- aggregationshemmung.Rest, mean, for the treatment of increased intraocular pressure and for cytoprotection, ulcer healing, inhibition of gastric acid secretion, luteolysis, blood pressure lowering or inhibition of platelet aggregation.
3. Verwendung von 9-Chlorprostaglandinderivaten nach Ansprach 1 und 2 zur Herstel¬ lung von Arzneimitteln zur Behandlung des erhöhten Augeninnendrackes.3. Use of 9-chloroprostaglandin derivatives according to spoke 1 and 2 for the manufacture of medicaments for the treatment of the increased intraocular pressure.
4. 9-Chlor-prostaglandinester und -amide der allgemeinen Formel (I)4. 9-chloro-prostaglandin esters and amides of the general formula (I)
woπn woπn
X Sauerstoff oder CH2, R1 COOR2 wobei R2 einen gegebenenfalls substituierten Phenacyl-Rest darstellt, oder CONHR3 mit R3 in der Bedeutung eines gegebenenfalls substituierten C^-CiQ-Al yl-X is oxygen or CH2, R 1 COOR 2 where R 2 is an optionally substituted phenacyl radical, or CONHR 3 with R 3 is an optionally substituted C ^ -Ci Q -Al yl-
Restes, bedeuten, Rest, mean
5. Ester von 9-Chlor-prostaglandinen der allgemeinen Formel I5. Esters of 9-chloro prostaglandins of the general formula I
woπn woπn
X Sauerstoff oder CH2, undX is oxygen or CH2, and
Rl COOR2, wobei R2 einen gegebenenfalls substituierten C2-C3-Alkyl-,Rl COOR 2 , where R 2 is an optionally substituted C2-C3 alkyl,
Cyclopentyl-, Cyclohexyl-, Phenyl- oder Benzyl-Rest darstellt, bedeuten und deren Cyclodextrinclathrate.Cyclopentyl, cyclohexyl, phenyl or benzyl radical, mean and their cyclodextrin clathrates.
6. Verfahren zur Herstellung der 9-Chlor-prostaglandinester und -amide der Formel I, dadurch gekennzeichnet, daß man eine Verbindung der Formel II6. A process for the preparation of the 9-chloro-prostaglandin esters and amides of the formula I, characterized in that a compound of the formula II
woπnwoπn
X die oben angegebene Bedeutung aufweist, unter Zusatz einer geeigneten Base mit einem gegebenenfalls substituierten Halogenaceto- phenonderivat der allgemeinen Formel III X has the meaning given above, with the addition of a suitable base with an optionally substituted haloacetophenone derivative of the general formula III
woπnwoπn
R4 C1-C4-Alkyl-, Chlor, Brom, oder Iod undR 4 is C 1 -C 4 alkyl, chlorine, bromine, or iodine and
Hai Chlor oder Brom bedeuten, in einem polaren Lösungsmittel zu Verbindungen der allgemeinen Formel (la) umsetzt,Hai is chlorine or bromine, converted into compounds of the general formula (Ia) in a polar solvent,
oder einen Alkylester der allgemeinen Formel Ib or an alkyl ester of the general formula Ib
woπnwoπn
X die oben angegebene Bedeutung aufweist, ohne Lösungsmittel mit einem Amin der allgemeinen Formel IV H2N— RX has the meaning given above, without solvent with an amine of the general formula IV H 2 N - R
(IV)(IV)
zu Verbindungen der allgemeinen Formel Icto compounds of the general formula Ic
umsetzt. implements.
7. Verfahren zur Herstellung von Estern der 9-Chlor-prostaglandine der Formel I worin7. A process for the preparation of esters of 9-chloro-prostaglandins of the formula I wherein
X Sauerstoff oder CH2, undX is oxygen or CH2, and
Rl COOR2, wobei R2 einen gegebenenfalls substituierten C2-C3-Alkyl-, Cyclopentyl, Cyclohexyl-, Phenyl- oder Benzyl-Rest darstellt, bedeuten, dadurch gekennzeichnet, daß man in an sich bekannter Weise eine Verbindung derRl COOR 2 , wherein R 2 represents an optionally substituted C2-C3 alkyl, cyclopentyl, cyclohexyl, phenyl or benzyl radical, characterized in that a compound of the
Formel IIFormula II
ClCl
worin X die oben angegebene Bedeutung hat,where X has the meaning given above,
A. entweder in Gegenwart einer geeigneten Base in einem polaren Lösungsmittel mit einer Verbindung der allgemeinen Formel III Hal-R2 (HI' )A. either in the presence of a suitable base in a polar solvent with a compound of general formula III Hal-R 2 (HI ')
worin R2 die oben angegebenen Bedeutung hat, jedoch nicht Phenyl bedeutet, und Hai für Chlor, Brom oder lod steht,bei Temperaturen zwischen -80°C und 100°C umsetzt, und den entstandenen Ester isoliert oder in Gegenwart einer, geeigneten Base in einem polaren Lösungsmittel nach Aktivierung mit einem Carbodiimid wie z. B. Dicyclohexylcarbodiimid mit Phenol bei Temperaturen zwischen -30°C und 50°C umsetzt und den entstandenen Ester isoliert.wherein R 2 has the meaning given above, but does not mean phenyl, and Hai is chlorine, bromine or iodine, at temperatures between -80 ° C and 100 ° C, and the resulting ester isolated or in the presence of a suitable base in a polar solvent after activation with a carbodiimide such as e.g. B. dicyclohexylcarbodiimide with phenol at temperatures between -30 ° C and 50 ° C and the resulting ester isolated.
8. (5Z,13E)-(9R,llR,15S)-9-Chlor-15-cyclohexyl-ll,15-dihydroxy-16,17,18,19,20- pentanor-5,13-prostadiensäurephenacylester8. (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic acid phenacylester
9. (5Z,13E)-(9R,llR,15S)-9-Chlor-15-cyclohexyl-ll,15-dihydroxy-16,17,18,19,20-penta- nor-5,13-prostadiensäure-(3-hydroxypropyl)-amid9. (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-penta- nor-5,13-prostadienoic acid- (3-hydroxypropyl) amide
10. (5Z,13E)-(9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl-ll,15-dihydroxy- 16,17,18,19,20-pentanor-5,13-prostadiensäurephenacylester10. (5Z, 13E) - (9R, llR, 15S) -9-chloro-3-oxa-15-cyclohexyl-ll, 15-dihydroxy- 16,17,18,19,20-pentanor-5,13- phenyl prostate
11. (5Z,13E)-(9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl-ll,15-dihydroxy- 16,17,18,19,20-pentanor-5,13-prostadiensäure-(3-hydroxypropyl)-amid11. (5Z, 13E) - (9R, llR, 15S) -9-chloro-3-oxa-15-cyclohexyl-ll, 15-dihydroxy- 16,17,18,19,20-pentanor-5,13- prostadienoic acid (3-hydroxypropyl) amide
12. (5Z,13E)-(9R,llR,15S)-9-Chlor-15-cyclohexyl-ll,15-dihydroxy-16,17,18,19,20- pentanor-5,13-prostadiensäuremethylester12. (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic acid methyl ester
13. (5Z,13E)-(9R,llR,15S)-9-Chlor-15-cyclohexyl-ll,15-dihydroxy-16,17,18,19,20- pentanor-5,13-prostadiensäureethylester13. (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic acid ethyl ester
14. (5Z,13E)-(9R,llR,15S)-9-Chlor-l5-cyclohexyl-ll,15-dihydroxy-16,17,18,19,20- pentanor-5,13-prostadiensäureisopropylester 15. (5Z,13E)-(9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl-ll,14. (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15-cyclohexyl-II, 15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic acid isopropyl ester 15. (5Z, 13E) - (9R, IIR, 15S) -9-chloro-3-oxa-15-cyclohexyl-II,
15-dihydroxy- 16,17,18,19,20-pentanor-5,13-prostadiensäuremethylester15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic acid methyl ester
16. (5Z,13E)-(9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl-ll,15-dihydroxy- 16,17,18,19,20-pentanor-5,13-prostadiensäureethylester16. (5Z, 13E) - (9R, llR, 15S) -9-chloro-3-oxa-15-cyclohexyl-ll, 15-dihydroxy- 16,17,18,19,20-pentanor-5,13- prostadienoic acid ethyl ester
17. (5Z,13E)-(9R,llR,15S)-9-Chlor-3-oxa-15-cyclohexyl-ll,15-dihydroxy- 16,17,18,19,20-pentanor-5,13-prostadiensäureisopropylester17. (5Z, 13E) - (9R, llR, 15S) -9-chloro-3-oxa-15-cyclohexyl-ll, 15-dihydroxy- 16,17,18,19,20-pentanor-5,13- isopropyl prostadienate
18. (5Z,13E)-(9R,llR,15S)-9-Chlor-15 cyclohexyl-ll,15-dihydroxy-3-oxa- 16,17,18,19,20-pentanor-5,13-prostadiensäure-tert.-butylester18. (5Z, 13E) - (9R, IIR, 15S) -9-chloro-15 cyclohexyl-II, 15-dihydroxy-3-oxa- 16,17,18,19,20-pentanor-5,13-prostadienoic acid -tert.-butyl ester
19. Arzneimittel enthaltend eine oder mehrere Verbindungen aus den Ansprüchen 4 und 5 und übliche Hilfe- und Trägerstoffe. 19. Medicament containing one or more compounds from claims 4 and 5 and conventional auxiliaries and carriers.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19924229051 DE4229051A1 (en) | 1992-08-31 | 1992-08-31 | Pharmaceutical prepns. for treatment of elevated intraocular pressure - contg. 9-chloro-prostaglandin derivs. |
| DE4229048A DE4229048A1 (en) | 1992-08-31 | 1992-08-31 | New ester(s) of 9-chloro-prostaglandin(s) - useful in treatment of glaucoma and as diuretic agents |
| DE4229050 | 1992-08-31 | ||
| DE4229050A DE4229050A1 (en) | 1992-08-31 | 1992-08-31 | New esters and amides of 9-chloro-prostaglandins - useful, e.g., in treatment of glaucoma and as diuretic agents |
| DE4229051 | 1992-08-31 | ||
| DE4229048 | 1992-08-31 | ||
| PCT/DE1993/000809 WO1994005631A1 (en) | 1992-08-31 | 1993-08-31 | 9-chloroprostaglandin esters and amides and their use in the preparation of drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0656889A1 true EP0656889A1 (en) | 1995-06-14 |
| EP0656889B1 EP0656889B1 (en) | 1998-05-27 |
Family
ID=27204144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP93918946A Expired - Lifetime EP0656889B1 (en) | 1992-08-31 | 1993-08-31 | 9-chloroprostaglandin esters and amides and their use in the preparation of drugs |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0656889B1 (en) |
| JP (1) | JPH08500597A (en) |
| AT (1) | ATE166642T1 (en) |
| DE (1) | DE59308617D1 (en) |
| DK (1) | DK0656889T3 (en) |
| ES (1) | ES2118248T3 (en) |
| WO (1) | WO1994005631A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0652211A1 (en) * | 1992-07-24 | 1995-05-10 | Taisho Pharmaceutical Co. Ltd | Prostaglandin derivative |
| JP2769294B2 (en) * | 1993-12-15 | 1998-06-25 | アルコン ラボラトリーズ インコーポレイテッド | Topical ophthalmic compositions and prostaglandin compounds therefor |
| AU687906B2 (en) * | 1993-12-15 | 1998-03-05 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| US5807892A (en) * | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| WO1997023225A1 (en) * | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
| WO1997023226A1 (en) * | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Combinations of prostaglandins and miotics for lowering intraocular pressure |
| US5700835A (en) * | 1995-12-22 | 1997-12-23 | Alcon Laboratories, Inc. | 3-Oxa-D-prostaglandins for lowering IOP |
| CA2665081C (en) | 2006-10-02 | 2015-12-01 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2950027A1 (en) * | 1979-12-10 | 1981-06-11 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | 9-CHLORINE PROSTAGLAND DERIVATIVES, METHOD FOR THE PRODUCTION AND USE AS A MEDICINAL PRODUCT |
| DE3504044A1 (en) * | 1985-02-04 | 1986-08-07 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 9-HALOGEN PROSTAGLANDIN CLATHRATE AND THEIR USE AS A MEDICINAL PRODUCT |
| DE3510978A1 (en) * | 1985-03-22 | 1986-09-25 | Schering AG, Berlin und Bergkamen, 1000 Berlin | NEW 9-HALOGEN PROSTAGLANDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
| ES2054860T5 (en) * | 1987-07-17 | 2003-11-01 | Schering Ag | DERIVATIVES OF 9-HALOGEN- (Z) -PROSTAGLANDINAS, PROCEDURE FOR ITS PREPARATION AND ITS USE AS MEDICATIONS. |
| DE4008925A1 (en) * | 1990-03-16 | 1991-09-19 | Schering Ag | New clathrates of 9-chloro-prostaglandin(s) with beta-cyclodextrin |
| DE4036140A1 (en) * | 1990-11-09 | 1992-05-14 | Schering Ag | 9-HALOGEN-11SS-HYDROXY-PROSTAGLANDIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
-
1993
- 1993-08-31 DK DK93918946T patent/DK0656889T3/en active
- 1993-08-31 JP JP6506751A patent/JPH08500597A/en not_active Ceased
- 1993-08-31 AT AT93918946T patent/ATE166642T1/en not_active IP Right Cessation
- 1993-08-31 ES ES93918946T patent/ES2118248T3/en not_active Expired - Lifetime
- 1993-08-31 DE DE59308617T patent/DE59308617D1/en not_active Expired - Fee Related
- 1993-08-31 WO PCT/DE1993/000809 patent/WO1994005631A1/en active IP Right Grant
- 1993-08-31 EP EP93918946A patent/EP0656889B1/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9405631A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08500597A (en) | 1996-01-23 |
| DE59308617D1 (en) | 1998-07-02 |
| WO1994005631A1 (en) | 1994-03-17 |
| DK0656889T3 (en) | 1999-03-22 |
| EP0656889B1 (en) | 1998-05-27 |
| ES2118248T3 (en) | 1998-09-16 |
| ATE166642T1 (en) | 1998-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0299914B2 (en) | 9-Halogen (Z) prostaglandin derivatives, process for their production and their use as medicines | |
| DE69223157T2 (en) | OXYGEN-SUBSTITUTED DERIVATIVES OF NUCLEOPHIL NITROGEN OXIDE ADDUCTS AND THEIR USE AS NITROGEN OXIDE DONOR PRODRUGS | |
| AT392964B (en) | METHOD FOR PRODUCING NEW OPTICALLY ACTIVE OR RACEMIC PROSTAGLAND IN DERIVATIVES | |
| EP0030377A1 (en) | 9-Chloro-prostaglandin derivatives, process for their preparation and use as medicines | |
| EP0059158A2 (en) | Aza prostacyclins, their preparation and therapeutic applications | |
| DE3118360C2 (en) | ||
| EP0069696A2 (en) | Derivatives of 9-fluoroprostaglandin, process for their preparation and their use as medicaments | |
| DE68928551T2 (en) | Ocular hypotensive means | |
| WO1995006634A1 (en) | New 9-chloro-prostaglandin derivatives | |
| EP0215860A1 (en) | 9-halogenprostaglandines, process for their manufacture. | |
| EP0198829A1 (en) | 9-halogen-prostaglandine derivatives, preparation process and utilization thereof as drugs. | |
| DE2904655A1 (en) | PROSTACYCLINANALOGA | |
| DE2753244A1 (en) | NEW PROSTACYCLINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION | |
| EP0656889B1 (en) | 9-chloroprostaglandin esters and amides and their use in the preparation of drugs | |
| DE2641823A1 (en) | NEW PROSTAGLANDIN ANALOGA | |
| DE4229050A1 (en) | New esters and amides of 9-chloro-prostaglandins - useful, e.g., in treatment of glaucoma and as diuretic agents | |
| CH638773A5 (en) | Prostane derivatives and process for their preparation | |
| DE69116541T2 (en) | A SYNTHESIS METHOD FOR PROSTAGLAND DERIVATIVES | |
| EP0510154B1 (en) | 9-HALOGEN-11(Beta)-HYDROXY PROSTAGLANDIN DERIVATIVE, PROCESS FOR PRODUCING IT AND ITS USE AS A MEDICAMENT | |
| DE69606364T2 (en) | Prostaglandin derivatives | |
| DE4229051A1 (en) | Pharmaceutical prepns. for treatment of elevated intraocular pressure - contg. 9-chloro-prostaglandin derivs. | |
| DE2910474C2 (en) | ||
| DE4229048A1 (en) | New ester(s) of 9-chloro-prostaglandin(s) - useful in treatment of glaucoma and as diuretic agents | |
| CH640847A5 (en) | Process for preparing analogues of 5,6-dihydroprostacyclin | |
| DE69108326T2 (en) | 15-DEOXYPROSTAGLAND IN DERIVATIVE. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19941212 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
| 17Q | First examination report despatched |
Effective date: 19960716 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
| REF | Corresponds to: |
Ref document number: 166642 Country of ref document: AT Date of ref document: 19980615 Kind code of ref document: T |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REF | Corresponds to: |
Ref document number: 59308617 Country of ref document: DE Date of ref document: 19980702 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE |
|
| ITF | It: translation for a ep patent filed | ||
| GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 19980827 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2118248 Country of ref document: ES Kind code of ref document: T3 |
|
| ET | Fr: translation filed | ||
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed | ||
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20040706 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20040708 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20040709 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20040712 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20040713 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20040714 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20040715 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20040716 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20040719 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20040726 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20040727 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20040804 Year of fee payment: 12 Ref country code: BE Payment date: 20040804 Year of fee payment: 12 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050831 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050831 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050831 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050831 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050831 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050831 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050831 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050901 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050901 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060301 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060301 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060302 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20050831 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060428 |
|
| NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20060301 |
|
| EUG | Se: european patent has lapsed | ||
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20060428 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20050901 |
|
| BERE | Be: lapsed |
Owner name: *SCHERING A.G. Effective date: 20050831 |